<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="pmh70014" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Personal Ment Health</journal-id><journal-id journal-id-type="iso-abbrev">Personal Ment Health</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1932-863X</journal-id><journal-id journal-id-type="publisher-id">PMH</journal-id><journal-title-group><journal-title>Personality and Mental Health</journal-title></journal-title-group><issn pub-type="ppub">1932-8621</issn><issn pub-type="epub">1932-863X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11864820</article-id><article-id pub-id-type="doi">10.1002/pmh.70014</article-id><article-id pub-id-type="publisher-id">PMH70014</article-id><article-id pub-id-type="other">PMH-24-00208.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Factors That Influence Prescribing in Borderline Personality Disorder: A Systematic Review</article-title></title-group><contrib-group><contrib id="pmh70014-cr-0001" contrib-type="author" corresp="yes"><name><surname>Confue</surname><given-names>Joshua</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-3875-5528</contrib-id><xref rid="pmh70014-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pmh70014-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>jc517@bath.ac.uk</email></address></contrib><contrib id="pmh70014-cr-0002" contrib-type="author"><name><surname>Maidment</surname><given-names>Ian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4152-9704</contrib-id><xref rid="pmh70014-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="pmh70014-cr-0003" contrib-type="author"><name><surname>Jones</surname><given-names>Sarah</given-names></name><xref rid="pmh70014-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pmh70014-cr-0004" contrib-type="author"><name><surname>Jones</surname><given-names>Matthew</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2617-4098</contrib-id><xref rid="pmh70014-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff content-type="private-address" id="pmh70014-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>University of Bath</institution>
<city>Bath</city>
<country country="GB">UK</country>
</aff><aff content-type="private-address" id="pmh70014-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Lincolnshire Partnership Foundation Trust</institution>
<city>Lincoln</city>
<country country="GB">UK</country>
</aff><aff content-type="private-address" id="pmh70014-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Aston University</institution>
<city>Birmingham</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Joshua Confue (<email>jc517@bath.ac.uk</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>19</volume><issue seq="20">2</issue><issue-id pub-id-type="doi">10.1002/pmh.v19.2</issue-id><elocation-id>e70014</elocation-id><history>
<date date-type="rev-recd"><day>18</day><month>1</month><year>2025</year></date>
<date date-type="received"><day>31</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons, Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). Personality and Mental Health Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PMH-19-0.pdf"/><abstract><title>ABSTRACT</title><p>Borderline personality disorder (BPD) is a psychiatric condition characterised by pervasive patterns of thinking and feeling, which can lead to social dysfunction and poor mental health. BPD has a significant impact not just on individuals with the diagnosis but also on those around them. Currently, no medication is licenced for BPD. Despite this, it is common for people with BPD to be prescribed multiple psychotropics. All psychotropic medications are associated with adverse events. A systematic review was conducted to explore factors that influence prescribing in adult BPD patients. Searches were conducted of EMBASE, PsycINFO, PubMed, EThOS and Web of Science. One&#x02010;hundred and two unique studies were identified, of which 13 suitable studies with diverse methodologies were included in the final synthesis. Of these, seven studies produced quantitative results, whereas the remaining six produced qualitative results. The synthesis identified several demographic factors statistically associated with prescribing. Most notably, prescribing was more likely in older patients and those with comorbid conditions. In addition to demographic factors identified, two key themes were generated from analysis of qualitative data from both healthcare professionals (HCPs) and patients discussing drivers: that the patient&#x02010;HCP relationship and the care pathway are crucial to the prescribing process from both perspectives. Prescribing medications for BPD is common, but there is limited data on the factors that affect this prescribing choice. HCPs must be aware of their own roles and perceptions in their relationships with BPD patients so that patients receive the most suitable treatment.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pmh70014-kwd-0001">borderline personality disorder</kwd><kwd id="pmh70014-kwd-0002">emotionally unstable personality disorder</kwd><kwd id="pmh70014-kwd-0003">prescribing</kwd><kwd id="pmh70014-kwd-0004">systematic review</kwd></kwd-group><counts><fig-count count="2"/><table-count count="7"/><page-count count="22"/><word-count count="12300"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="pmh70014-ntgp-0001"><fn fn-type="funding" id="pmh70014-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="pmh70014-body-0001"><sec id="pmh70014-sec-0001"><label>1</label><title>Introduction</title><p>Borderline personality disorder (BPD) is a psychiatric condition that falls under the category of personality disorders (World Health Organization&#x000a0;<xref rid="pmh70014-bib-0054" ref-type="bibr">2019</xref>). Although we understand that labelling these complex presentations is controversial, we have used the term <italic toggle="yes">borderline personality disorder</italic> for clarity, because it is widely accepted and used in National Institute of Health and Care Excellent (NICE) Clinical Guidelines. It is characterised by pervasive patterns of thinking and feeling, which can lead to social dysfunction and poor mental health (Paton et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0032" ref-type="bibr">2015</xref>). Estimates of the prevalence of BPD in the general population vary, not only based on different diagnostic criteria and assessment processes but also across geographical locations (Shin et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0040" ref-type="bibr">2023</xref>). For instance, a 2006 review suggested that the weighted prevalence of the condition is 4.4% in the United Kingdom (Coid et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0009" ref-type="bibr">2006</xref>), whereas a 2014 study, based on data from the United States National Epidemiologic Survey on Alcohol and Related Conditions, estimated the prevalence in the United States to be about half this, at 2.7% (ten Have et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0048" ref-type="bibr">2016</xref>). Overall, population&#x02010;based survey studies show a prevalence range between 0.7% and 5.9% (Shin et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0040" ref-type="bibr">2023</xref>).</p><p>The condition can result in a high burden for patients, family members and healthcare systems (Bohus et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0003" ref-type="bibr">2021</xref>). One prospective follow&#x02010;up study found that four times as many patients with BPD die of suicide compared with the general population, with all&#x02010;cause mortality found to be three times higher in BPD patients (Temes et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0047" ref-type="bibr">2019</xref>).</p><p>The economic impact of personality disorders is challenging to estimate, but the costs are significant and thought to be rising (Botham et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0004" ref-type="bibr">2024</xref>). In England, a 2008 King's Fund report estimated the annual service cost per patient for those in contact with primary care teams at &#x000a3;286 (McCrone and King's Fund&#x000a0;<xref rid="pmh70014-bib-0023" ref-type="bibr">2008</xref>). The total estimated annual cost was &#x000a3;704 million in 2007, along with additional loss of employment costs amounting to &#x000a3;7.9 billion (McCrone and King's Fund&#x000a0;<xref rid="pmh70014-bib-0023" ref-type="bibr">2008</xref>). These figures were projected to rise significantly to &#x000a3;1.1 billion by 2026, with an alarming loss of employment cost of &#x000a3;12.3 billion (McCrone and King's Fund&#x000a0;<xref rid="pmh70014-bib-0023" ref-type="bibr">2008</xref>).</p><p>A corresponding study in the Netherlands (with a population of about 15% of the UK's) estimated the societal costs of BPD to be around &#x020ac;2222 million yearly, only 22% of which were healthcare related. Although this study consists of a relatively small number of participants (88), it does provide data over a substantial period (14&#x02009;years) and provides further evidence of the societal costs of this condition (van Asselt et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0051" ref-type="bibr">2007</xref>).</p><p>The evidence base for the use of medication in managing BPD is conflicted. The validity of BPD as a diagnostic construct is still disputed, and this may help explain some of the challenges in generating robust evidence in regards to its treatment (Tedesco et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0046" ref-type="bibr">2024</xref>). Currently, no medication is licenced for BPD in the United Kingdom, Europe or America (Abel et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0001" ref-type="bibr">2018</xref>; Silk&#x000a0;<xref rid="pmh70014-bib-0042" ref-type="bibr">2015</xref>). It is also noteworthy that the American Association of Psychiatrists, the National Health and Medical Research Council of Australia and NICE of England, among other major institutions, concur on the recommendation of psychotherapy as the primary treatment for BPD, over psychotropic medication, due to the lack of sufficient evidence on the clinical effectiveness of medication (Bridler et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0005" ref-type="bibr">2015</xref>).</p><p>In particular, NICE's recommendation that psychotropic medication should not be used as a treatment for BPD draws upon the findings of an extensive, well&#x02010;structured 2010 Cochrane review (Lieb et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0019" ref-type="bibr">2010</xref>), which examined 27 trials to evaluate the effectiveness of pharmacological therapy in BPD. It concluded that mood stabilisers and second&#x02010;generation antipsychotics had the most beneficial effects. However, the authors noted that this conclusion was based mostly on single, small studies and that treatment should be symptom specific.</p><p>A 2022 update to this review included a further 18 trials. However, it once again found very low&#x02010;certainty evidence and concluded that medication most likely results in no difference in any primary outcome (Stoffers&#x02010;Winterling et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0044" ref-type="bibr">2022</xref>). Overall, the update supported the continued stance that no pharmacological therapy seems effective in treating BPD specifically (Stoffers&#x02010;Winterling et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0044" ref-type="bibr">2022</xref>).</p><p>In practice, however, it is common for people with BPD to be prescribed psychotropic medications. In 2014, the Prescribing Observatory for Mental Health (POMH&#x02010;UK) conducted a national audit in England, with all National Health Service organisations that provide specialist mental health services invited to report on prescribing in BPD. Of the 60 applicable organisations, 41 submitted information on 2600 randomly selected patients. The audit showed that over 70% of patients were prescribed an antipsychotic and more than 50% were prescribed a sedative, with these prescriptions overlapping in multiple cases (POMH&#x02010;UK&#x000a0;<xref rid="pmh70014-bib-0033" ref-type="bibr">2014</xref>).</p><p>A 2015 inpatient study across Europe supports this picture of high prescribing levels. Of 2195 inpatients identified with BPD between 2001 and 2011, 70% were found to be prescribed antipsychotics, antidepressants or both, and 30% were prescribed benzodiazepines (Bridler et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0005" ref-type="bibr">2015</xref>). Perhaps most notably, over half of the patients received three or more psychotropic medications concomitantly (Bridler et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0005" ref-type="bibr">2015</xref>).</p><p>There is a noticeable contrast between the national guidance based on the current evidence base and the observed real&#x02010;world practice. To understand this discrepancy, it is essential to explore the factors that influence the prescribing of medication to patients with BPD. The existing evidence regarding the prescribing influences indicates a large number of potential factors (Schumock et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0038" ref-type="bibr">2004</xref>). It is worth noting at this juncture that there are a number of potential reasons why prescribing in psychiatric conditions may differ from other specialities. These reasons include, but are not limited to, diagnostic complexity, individualised treatment response and the subjective nature of psychiatric conditions. This review's aim was to evaluate the current practices and identify the factors that impact the prescribing of medication to BPD patients.</p></sec><sec id="pmh70014-sec-0002"><label>2</label><title>Methodology&#x02014;Systematic</title><p>This review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;Analyses (PRISMA) guidelines (Page et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0027" ref-type="bibr">2021</xref>) (compliance table Appendix&#x000a0;<xref rid="pmh70014-app-0001" ref-type="app">A</xref>), and the protocol was registered on PROSPERO (Registration No. CRD42023422571). Ethical approval was not required, as the study only involved secondary analysis of anonymised data.</p><sec id="pmh70014-sec-0003"><label>2.1</label><title>Research Question and Context</title><p>The research question was constructed through an iterative review of the topic of prescribing in BPD. The research team was comprised of four pharmacists with speciality, psychiatric and systematic review experience.</p><p>The use of structured, systematic search strategies helps to facilitate high&#x02010;quality research. As such, SPIDER was utilised, which was adapted from the PICO framework (Methley et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0024" ref-type="bibr">2014</xref>), given the expected results of mixed methods and qualitative research. The final research question is as follows:</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0001"><p>What factors influence the decision to prescribe medication in the management of adult patients with borderline personality disorder?</p></disp-quote>
</p></sec><sec id="pmh70014-sec-0004"><label>2.2</label><title>Search Strategy</title><p>The review team developed a search strategy with input from a Health Sciences Librarian, which was subsequently peer&#x02010;reviewed by four supporting experts (Appendix&#x000a0;<xref rid="pmh70014-app-0002" ref-type="app">B</xref>).</p><p>The following electronic information sources were searched: EMBASE (Elsevier), PsycINFO (EBSCOhost), PubMed (MEDLINE), Ethos (Grey Literature) and Web of Science. Searches were conducted on 11 September 2023 and rerun on 23 September 2024. Forward&#x02010;searching was conducted by manually reviewing the reference lists of included studies.</p></sec><sec id="pmh70014-sec-0005"><label>2.3</label><title>Inclusion and Exclusion Criteria</title><p>The criteria for study selection were generated based on mapping the research question, as described below.</p><p>The included studies
<list list-type="order" id="pmh70014-list-0001"><list-item id="pmh70014-li-0001"><p>pertained to individuals who were 18&#x02009;years and older and had been prescribed medication for, or with, a diagnosis of BPD, including individuals with comorbid psychiatric conditions (studies including patients aged &#x0003c;&#x02009;18&#x02009;years were included if relevant data could be extracted);</p></list-item><list-item id="pmh70014-li-0002"><p>investigated pharmacological interventions, entailing all psychotropic medication utilised in the management of BPD, including but not limited to antidepressants, sedatives, benzodiazepines, antipsychotics and mood stabilisers (studies pertaining to herbal supplements and homoeopathy were not included);</p></list-item><list-item id="pmh70014-li-0003"><p>explored or described factors influencing prescribing for medical and nonmedical prescribers. This included, but was not limited to, prescriber characteristics, patient characteristics, medication type and healthcare service design; and</p></list-item><list-item id="pmh70014-li-0004"><p>were pieces of primary research of any design, published in full in English, conducted after the publication of the Diagnostic and Statistical Manual of Mental Disorders IV (1994), due to changes in diagnostic criteria between DSM&#x02010;III and DSM&#x02010;IV criteria (with the addition of the ninth criterion, &#x02018;transient, stress&#x02010;related paranoid ideation or severe dissociative symptoms&#x02019;) (Silk&#x000a0;<xref rid="pmh70014-bib-0041" ref-type="bibr">2002</xref>).</p></list-item></list>
</p></sec><sec id="pmh70014-sec-0006"><label>2.4</label><title>Study Selection</title><p>After completing the searches, the data were imported into EndNote to remove duplicates. Subsequently, the remaining data were imported into Rayyan (<ext-link xlink:href="http://www.rayyan.ai" ext-link-type="uri">www.rayyan.ai</ext-link>) for further processing. The study selection process consisted of two stages.</p><p>In Stage 1, all the studies' titles and abstracts were evaluated according to the inclusion and exclusion criteria. In case of doubt, studies were included at this stage and progressed to the next stage.</p><p>In Stage 2, the full texts of the retained studies were obtained and evaluated according to the inclusion and exclusion criteria. If the full text could not be obtained, the study was excluded. Any excluded study was documented, along with the reason for exclusion (Figure&#x000a0;<xref rid="pmh70014-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="pmh70014-fig-0001"><label>FIGURE 1</label><caption><p>PRISMA diagram.</p></caption><graphic xlink:href="PMH-19-0-g002" position="anchor" id="jats-graphic-1"/></fig><p>Two review team members (JC and SJ) made independent decisions regarding each study for both stages. If there was disagreement, they discussed and tried to reach a consensus. If a consensus could not be reached, a third member was consulted to make the final decision.</p></sec><sec id="pmh70014-sec-0007"><label>2.5</label><title>Data Extraction</title><p>An electronic data extraction form was created on a standardised Microsoft Excel spreadsheet based on the review question and objectives in consultation with all team members (Appendix&#x000a0;<xref rid="pmh70014-app-0003" ref-type="app">C</xref>), following the guidelines provided by PRISMA (Page et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0027" ref-type="bibr">2021</xref>). Data were extracted by a single reviewer (JC) and then reviewed by a second reviewer (SJ).</p></sec><sec id="pmh70014-sec-0008"><label>2.6</label><title>Assessment of Quality</title><p>To assess the quality of each study selected for inclusion, the lead reviewer (JC) used the Mixed Methods Appraisal Tool (MMAT) (Nha Hong et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0025" ref-type="bibr">2018</xref>) to evaluate the risk of bias in each study. Studies were grouped based on qualitative or quantitative results before being assessed based on their described methodology.</p></sec><sec id="pmh70014-sec-0009"><label>2.7</label><title>Analysis</title><p>Following the completion of searches, it was determined that meta&#x02010;analysis was an unsuitable approach due to the significant heterogeneity in the studies selected for inclusion. Therefore, the team summarised the findings through a narrative synthesis, focused on the prescribing processes. This methodology allowed for a flexible approach, encompassing the range of methodologies, populations, and results reported in the identified studies (Ryan&#x000a0;<xref rid="pmh70014-bib-0035" ref-type="bibr">2016</xref>; Sukhera&#x000a0;<xref rid="pmh70014-bib-0045" ref-type="bibr">2022</xref>).</p><p>Findings from the included studies were analysed through results&#x02010;based, convergent synthesis design (Noyes et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0071" ref-type="bibr">2019</xref>). Quantitative studies with numerical results were analysed using numerical analysis; descriptive statistics were utilised, and the results were grouped according to prescribing factors. Thematic data were analysed using a modified inductive thematic analysis approach based on Braun and Clarke's method (Byrne&#x000a0;<xref rid="pmh70014-bib-0006" ref-type="bibr">2022</xref>). Qualitative outcome studies were reviewed to derive codes and subcodes representing information useful in addressing the research question by the lead reviewer (JC). These codes were then developed into descriptive themes and grouped by the stakeholders' nature (healthcare professional [HCP] or patient/carer) with input from four members of the team (JC, SJ, IM and MJ). Subsequently, these themes were defined and interpreted to develop a descriptive format.</p><p>Finally, the project team combined the results of both numerical and thematic analyses into the narrative discussion. The ENTREQ reporting guidelines were used for this review (Tong et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0050" ref-type="bibr">2012</xref>) (Appendix&#x000a0;<xref rid="pmh70014-app-0004" ref-type="app">D</xref>).</p></sec></sec><sec sec-type="results" id="pmh70014-sec-0010"><label>3</label><title>Results</title><p>The searches identified 133 records, from which 13 studies were selected for inclusion in the review (Figure&#x000a0;<xref rid="pmh70014-fig-0001" ref-type="fig">1</xref>). Table&#x000a0;<xref rid="pmh70014-tbl-0001" ref-type="table">1</xref> presents an overview of the included studies. The selected articles demonstrated significant variations in study design, including semistructured interviews, Delphi studies, quantitative cross&#x02010;sectional surveys and retrospective observational studies. The included studies were predominantly conducted in the United Kingdom, with additional studies from Europe, Iran and the United States. The number of participants varied widely, with sample sizes ranging from 9 to 550 participants (Table&#x000a0;<xref rid="pmh70014-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="pmh70014-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Included studies characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Crawford et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0011" ref-type="bibr">2011</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Knappich et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0017" ref-type="bibr">2014</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Tong et&#x000a0;al. (<xref rid="pmh70014-bib-0066" ref-type="bibr">2021</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mirhaj Mohammadabadi et&#x000a0;al. (<xref rid="pmh70014-bib-0067" ref-type="bibr">2022</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Martean and Evans&#x000a0;(<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Dickens et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0013" ref-type="bibr">2016</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Wlodarczyk et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patel and Konstantinidou (<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Schulkens et&#x000a0;al. (<xref rid="pmh70014-bib-0068" ref-type="bibr">2021</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Javed et&#x000a0;al. (<xref rid="pmh70014-bib-0069" ref-type="bibr">2022</xref>)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Research outcome type</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Numerical</td><td align="center" valign="top" rowspan="1" colspan="1">Thematic</td><td align="center" valign="top" rowspan="1" colspan="1">Thematic</td><td align="center" valign="top" rowspan="1" colspan="1">Thematic</td><td align="center" valign="top" rowspan="1" colspan="1">Thematic</td><td align="center" valign="top" rowspan="1" colspan="1">Thematic</td><td align="center" valign="top" rowspan="1" colspan="1">Thematic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study design</td><td align="center" valign="top" rowspan="1" colspan="1">Retrospective observational Study</td><td align="center" valign="top" rowspan="1" colspan="1">Retrospective naturalistic study</td><td align="center" valign="top" rowspan="1" colspan="1">Retrospective observational study</td><td align="center" valign="top" rowspan="1" colspan="1">Questionnaire</td><td align="center" valign="top" rowspan="1" colspan="1">Observational cross&#x02010;sectional study</td><td align="center" valign="top" rowspan="1" colspan="1">Observational cross&#x02010;sectional study</td><td align="center" valign="top" rowspan="1" colspan="1">Cross&#x02010;sectional questionnaire</td><td align="center" valign="top" rowspan="1" colspan="1">Semistructured interview</td><td align="center" valign="top" rowspan="1" colspan="1">Semistructured interview</td><td align="center" valign="top" rowspan="1" colspan="1">Focus groups</td><td align="center" valign="top" rowspan="1" colspan="1">Focus groups</td><td align="center" valign="top" rowspan="1" colspan="1">Delphi</td><td align="center" valign="top" rowspan="1" colspan="1">Questionnaire</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Country/countries from which study participants were recruited</td><td align="center" valign="top" rowspan="1" colspan="1">Spain</td><td align="center" valign="top" rowspan="1" colspan="1">Spain</td><td align="center" valign="top" rowspan="1" colspan="1">United Kingdom (England)</td><td align="center" valign="top" rowspan="1" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="top" rowspan="1" colspan="1">Spain</td><td align="center" valign="top" rowspan="1" colspan="1">Iran</td><td align="center" valign="top" rowspan="1" colspan="1">United Kingdom (England)</td><td align="center" valign="top" rowspan="1" colspan="1">United Kingdom (England)</td><td align="center" valign="top" rowspan="1" colspan="1">South Australia</td><td align="center" valign="top" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="top" rowspan="1" colspan="1">Netherlands, Belgium, United Kingdom, United States, Switzerland, Australia</td><td align="center" valign="top" rowspan="1" colspan="1">United Kingdom (England)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Setting</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services (emergency)</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Private psychiatric practice</td><td align="center" valign="top" rowspan="1" colspan="1">Across services</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Primary care services</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary Care psychiatric services</td><td align="center" valign="top" rowspan="1" colspan="1">Across settings</td><td align="center" valign="top" rowspan="1" colspan="1">Secondary care psychiatric services</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Participants</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">Consultant Psychiatrists</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">Consultant psychiatrists</td><td align="center" valign="top" rowspan="1" colspan="1">Patients</td><td align="center" valign="top" rowspan="1" colspan="1">GPs, university&#x02010;based researchers, psychiatrists, PATIENTS</td><td align="center" valign="top" rowspan="1" colspan="1">Patients (in group therapy)</td><td align="center" valign="top" rowspan="1" colspan="1">Experts (inclusion criteria provided in study, but breakdown of participants not reported)</td><td align="center" valign="top" rowspan="1" colspan="1">Medical prescribers (consultants, staff grade doctors or higher level trainees)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of participants</td><td align="center" valign="top" rowspan="1" colspan="1">540</td><td align="center" valign="top" rowspan="1" colspan="1">226</td><td align="center" valign="top" rowspan="1" colspan="1">332</td><td align="center" valign="top" rowspan="1" colspan="1">141</td><td align="center" valign="top" rowspan="1" colspan="1">51</td><td align="center" valign="top" rowspan="1" colspan="1">620</td><td align="center" valign="top" rowspan="1" colspan="1">64</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">22 (12 GPs, 10 other stakeholders)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>7</p>
<p>(4 and 3 across two focus groups)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 31.3</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 28.9</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 42.5</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 51.7</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 35.7</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 30.4</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 33.6</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">Mean age 27.8</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">20&#x02013;54 (Mean age not provided)</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">% Female</td><td align="center" valign="top" rowspan="1" colspan="1">11.7%</td><td align="center" valign="top" rowspan="1" colspan="1">85.8%</td><td align="center" valign="top" rowspan="1" colspan="1">49.4%</td><td align="center" valign="top" rowspan="1" colspan="1">59.0%</td><td align="center" valign="top" rowspan="1" colspan="1">39.2%</td><td align="center" valign="top" rowspan="1" colspan="1">88.0%</td><td align="center" valign="top" rowspan="1" colspan="1">84.4%</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">100.0%</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">57.1%</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">% Male</td><td align="center" valign="top" rowspan="1" colspan="1">88.3%</td><td align="center" valign="top" rowspan="1" colspan="1">14.2%</td><td align="center" valign="top" rowspan="1" colspan="1">50.6%</td><td align="center" valign="top" rowspan="1" colspan="1">41.0%</td><td align="center" valign="top" rowspan="1" colspan="1">60.8%</td><td align="center" valign="top" rowspan="1" colspan="1">12.0%</td><td align="center" valign="top" rowspan="1" colspan="1">15.6%</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">0.0%</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">42.9%</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td><td align="center" valign="top" rowspan="1" colspan="1">Not provided</td></tr></tbody></table><table-wrap-foot id="pmh70014-ntgp-0002"><fn id="pmh70014-note-0002"><p>Abbreviation: GP, general practitioner.</p></fn></table-wrap-foot></table-wrap><p>Seven studies produced numerical results reporting on factors associated with prescribing, two of which also reported on the value of treatment adherence. Table&#x000a0;<xref rid="pmh70014-tbl-0002" ref-type="table">2</xref> provides a summary of these results. Six studies produced thematic results reporting themes related to the prescribing process, as summarised in Table&#x000a0;<xref rid="pmh70014-tbl-0003" ref-type="table">3</xref>.</p><table-wrap position="float" id="pmh70014-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Numerical outcomes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Crawford et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0011" ref-type="bibr">2011</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Knappich et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0017" ref-type="bibr">2014</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Tong et&#x000a0;al. (<xref rid="pmh70014-bib-0066" ref-type="bibr">2021</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mirhaj Mohammadabadi et&#x000a0;al. (<xref rid="pmh70014-bib-0067" ref-type="bibr">2022</xref>)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Factors associated with prescription</td><td align="center" valign="top" rowspan="1" colspan="1">Factors associated with prescription</td><td align="center" valign="top" rowspan="1" colspan="1">Factors associated with prescription</td><td align="center" valign="top" rowspan="1" colspan="1">Value of pharmacotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Factors associated with prescription</td><td align="center" valign="top" rowspan="1" colspan="1">Factors associated with prescription</td><td align="center" valign="top" rowspan="1" colspan="1">Treatment adherence to pharmacological intervention</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Outcome details general</p>
<p>Factors influencing prescribing regardless of medication class</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>&#x0003e;&#x02009;80% of patients prescribed medication</p>
<p>Presence of comorbid condition is the biggest predictor of prescribing.</p>
<p>Medication prescription is more likely in patients with:</p>
<p>&#x02010; Comorbid depression (OR 3.0, CI 95% 1.4&#x02013;6.5)</p>
<p>&#x02010; Substance misuse (OR 3.0, 95% CI 1.4&#x02013;6.5).</p>
<p>&#x02010; Specialist PACT Treatment (OR 0.35, CI 95% 0.13&#x02013;0.95)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>50% of patients were on three or more medications</p>
<p>BPD patients are more likely to self&#x02010;harm (OR 2.3, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.005) (x29.204, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002)</p>
<p>BPD patients are not more likely to have forensic history (x2&#x02009;=&#x02009;0.337 <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.561)</p>
<p>BPD patients are not more likely to suffer from alcohol or illicit substance abuse (statistical analysis not provided)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Medication prescription is more likely in:</p>
<p>&#x02010; older patients (mean age 30.9 vs. 27.3 <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0002)</p>
<p>&#x02010; patients with comorbid psychiatric conditions: 77.8% vs. 58.2% (OR 2.5, 95% CI 1.5&#x02013;4.2)</p>
<p>Polypharmacy is more likely in:</p>
<p>&#x02010; older patients (mean age 31.9 vs. 29 <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001)</p>
<p>&#x02010; patients with comorbid psychiatric condition: 83.2% vs 67.5% (OR 2.4, 95% CI 1.6&#x02013;3.6)</p>
<p>The regression model associated the following factors with polypharmacy:&#x02010; affective, anxiety, and eating disorder symptoms (AUC 0.707, 95% CI 0.667&#x02013;0.748)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Gender, occupation, education, marriage, and hospitalisation have no effect on self&#x02010;reported adherence to medication</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Factors influencing prescribing of antidepressants</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>Antidepressant prescription is associated with age, comorbid conditions, affective and anxiety symptoms</p>
<p>Antidepressant prescription is nearly three times as likely in the presence of comorbid anxiety disorder (OR 2.77, 95% CI 1.16&#x02013;6.1)</p>
<p>SSRI prescriptions associated with eating disorders (OR 2.01, 95% CI 1.12&#x02013;3.61)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>Antidepressants were the most commonly prescribed agent</p>
<p>&#x0003e;&#x02009;90% of BPD patients were prescribed one or more antidepressants</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Factors influencing prescribing of benzodiazepine</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Benzodiazepine prescription is more likely in:</p>
<p>&#x02010; male patients (female OR 0.63, 95% CI 0.42&#x02013;0.88)</p>
<p>&#x02010; patients with anxiety (OR 3.77, 95% CI 2.52&#x02013;5.66)</p>
<p>Benzodiazepine prescription is less likely in patients with:</p>
<p>&#x02010; issues with self&#x02010;care (OR 0.61, CI 96% 0.42&#x02013;0.88)</p>
<p>&#x02010; drug problems (OR 0.58, CI 95% 0.38&#x02013;0.88)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Benzodiazepine prescription is more likely in:</p>
<p>&#x02010; older female patients ()</p>
<p>Benzodiazepine prescription is less likely in patients with:</p>
<p>&#x02010; substance misuse disorder comorbidity (OR 0.45, 95% CI 0.24&#x02013;0.87)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>Benzodiazepines were prescribed by 71.4% of psychiatrists</p>
<p>60% of respondents selected benzodiazepines for their anxiety&#x02010;reducing effects.</p>
<p>16% of respondents selected a benzodiazepine based on the shortness of its half&#x02010;life.</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Factors influencing prescribing of mood stabilisers</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>Mood stabiliser prescription is more likely in:</p>
<p>&#x02010; older patients with less severe symptoms (based on DIB&#x02010;R scale)</p>
<p>&#x02010; the presence of comorbid anxiety disorder (OR 2.95, 95% CI 1.04&#x02013;3.69)</p>
<p>&#x02010; patients with previous hospitalisation (OR 2.82, 95% CI 1.48&#x02013;5.36)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>Mood stabilisers were prescribed by 74.6% of psychiatrists</p>
<p>Agent most commonly prescribed was valproate (no reason given)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Factors influencing prescribing of antipsychotics</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Antipsychotic prescription is more likely in:</p>
<p>&#x02010; male patients (female OR 0.63, CI 95% 0.43&#x02013;09.4)</p>
<p>&#x02010; patients presenting higher risk to others (OR 2.07, CI 95% 1.39&#x02013;3.06)</p>
<p>&#x02010; patients with a history of drug use (statistics not provided)</p>
<p>&#x02010; patients with psychosis in symptomatology (OR 6.88, 95% CI 1.64&#x02013;28.90)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Antipsychotic prescription is more likely in:</p>
<p>&#x02010; older men with higher impulsivity and affective scores, and substance misuse</p>
<p>&#x02010; patients with previous hospitalisation (OR 1.89, 95% CI 1.0.1&#x02013;3.54)</p>
<p>&#x02010; patients with higher impulsivity scores (OR 1.77, 95% CI 1.09&#x02013;2.87)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<p>92.2% of respondents selected a second generation antipsychotic</p>
<p>70.1% of respondents stated that the agent most commonly prescribed was quetiapine (no reason given)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="pmh70014-ntgp-0003"><fn id="pmh70014-note-0003"><p>Abbreviations: AUC, area under curve; BPD, borderline personality disorder; CI, confidence interval; DIB&#x02010;R, Diagnostic Interview for Borderlines (Revised); OR, odds ratio; PACT, Personality and Complex Trauma team.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pmh70014-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Thematic outcomes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Dickens et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0013" ref-type="bibr">2016</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Martean and Evans&#x000a0;<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Schulkens et&#x000a0;al. <xref rid="pmh70014-bib-0068" ref-type="bibr">2021</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Javed et&#x000a0;al. <xref rid="pmh70014-bib-0069" ref-type="bibr">2022</xref>
</th></tr><tr><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Themes</th><th align="center" valign="bottom" rowspan="1" colspan="1">Themes (and subthemes)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Themes, challenges and strategies</th><th align="center" valign="bottom" rowspan="1" colspan="1">Themes</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment algorithm</th><th align="center" valign="bottom" rowspan="1" colspan="1">Themes</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Number of Outcomes</th><th align="center" valign="bottom" rowspan="1" colspan="1">4 themes</th><th align="center" valign="bottom" rowspan="1" colspan="1">4 themes</th><th align="center" valign="bottom" rowspan="1" colspan="1">4</th><th align="center" valign="bottom" rowspan="1" colspan="1">5</th><th align="center" valign="bottom" rowspan="1" colspan="1">4 algorithm nodes</th><th align="center" valign="bottom" rowspan="1" colspan="1">13</th></tr></thead><tbody valign="top"><tr><td rowspan="13" align="left" valign="top" colspan="1">Themes influencing prescribing in patients with BPD</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Difficulty collaborating in emotionally charged situations (H)</td><td align="center" valign="top" rowspan="1" colspan="1">Challenges around diagnosis (H)</td><td align="center" valign="top" rowspan="1" colspan="1">Medication has a powerful impact on the body and mind (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Presence of cognitive&#x02010;perceptual symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">Symptomatic treatment (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Wellbeing (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Feeling helpless, unable to relieve suffering (H)</td><td align="center" valign="top" rowspan="1" colspan="1">Comorbidities and clinical complexity (H)</td><td align="center" valign="top" rowspan="1" colspan="1">Confronting the powerful position of doctors (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Impulsive behaviour</td><td align="center" valign="top" rowspan="1" colspan="1">Balancing psychological and pharmacological treatment (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Understanding (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Drugs as a facilitator of the doctor&#x02013;patient relationship (H)</td><td align="center" valign="top" rowspan="1" colspan="1">Difficulties with patient behaviour and GP relationship (H)</td><td align="center" valign="top" rowspan="1" colspan="1">[Medication as a] moderator to the prescribing experience(P)</td><td align="center" valign="top" rowspan="1" colspan="1">Affective dysregulation</td><td align="center" valign="top" rowspan="1" colspan="1">Treating other comorbidity (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Self&#x02010;management (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Effects of discontinuing [medication] on doctor&#x02010;patient relationship (H)</td><td align="center" valign="top" rowspan="1" colspan="1">Finding and navigating the system for support (H)</td><td align="center" valign="top" rowspan="1" colspan="1">[Patients'] expectations of healthcare professional (P)</td><td align="center" valign="top" rowspan="1" colspan="1">Previous treatment</td><td align="center" valign="top" rowspan="1" colspan="1">Feeling pressured [from] high expectations from service users (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Needing a relationship with the doctor (P)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">NICE guidelines restrict clinicians' prescribing (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Limited evidence for prescribing</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Clinicians fear intensifying feelings of anger from not prescribing and self&#x02010;harm (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Practical challenges [of] following guidelines (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Evidence&#x02010;based prescribing (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Experience based on service users' previous response (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Feeling uncomfortable/discomfort due to patient response (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Feeling stuck with established prescriptions (H)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Inadvertent risk (H)</td></tr></tbody></table><table-wrap-foot id="pmh70014-ntgp-0004"><fn id="pmh70014-note-0004"><p>
<italic toggle="yes">Note:</italic> Bracket words in themes have been added to provide context and clarity.</p></fn><fn id="pmh70014-note-0005"><p>Abbreviations: GP, general practitioner; (H), health care professional; NICE, National Institute of Care and Clinical Excellence. (P), patient.</p></fn></table-wrap-foot></table-wrap><sec id="pmh70014-sec-0011"><label>3.1</label><title>Risk of Bias and Quality Assessment</title><p>The MMAT focuses on five sets of criteria for different study designs. This enables the evaluation of methodological distinctions in studies within the review using a single tool (Nha Hong et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0025" ref-type="bibr">2018</xref>). Following evaluation, all 13 studies were included in the synthesis, with more weight given to more rigorous studies in the thematic analysis (Appendix&#x000a0;<xref rid="pmh70014-app-0005" ref-type="app">E</xref>). No randomised controlled studies were found, and the variation in the assessment of results and the definition of medication groups added complexity to the interpretation. Most of the identified studies had relatively small sample sizes, and even the larger studies were often retrospective or observational, limiting the conclusions that could be drawn. The overall robustness of the findings must be considered low, largely due to the scarcity of available data.</p></sec><sec id="pmh70014-sec-0012"><label>3.2</label><title>Demographic Factors</title><p>The section below describes quantitative data, regarding factors associated with prescribing in BPD. Six patient demographics were associated with medication prescribing in BPD: comorbidity, age, hospitalisation, gender, presentation of risk and severity of presentation. Only comorbidity and age were reported to be associated with prescribing regardless of medication class.</p><sec id="pmh70014-sec-0013"><label>3.2.1</label><title>Comorbidity</title><p>Comorbidity&#x02014;here defined as the presence of an additional psychiatric condition&#x02014;was associated, in two identified studies, with an increased probability of prescribing regardless of medication class utilised. In both these studies, comorbid psychiatric conditions were identified as a significant predictor of prescribing (Crawford et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0011" ref-type="bibr">2011</xref>; Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>).</p><p>A 2011 UK study found that comorbid depression was the most significant predictor of prescribing, with an odds ratio (OR) of 3.0 (95% confidence interval [CI] 1.4&#x02013;6.5) (Crawford et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0011" ref-type="bibr">2011</xref>). This conclusion was further supported by a subsequent 2021 study of over 600 records, which found that individuals were more likely to be prescribed medication if they had a comorbid psychiatric condition (77.8% vs. 58.2%) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>).</p><p>However, certain comorbid conditions were associated with the prescribing of specific medication classes. One study reported that antidepressant prescribing was more likely in the presence of comorbid conditions, particularly anxiety&#x02010;related disorders (OR 2.77, 95% CI 1.16&#x02013;6.1) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). Comparatively, antipsychotic prescribing was found to be more common in the presence of psychosis symptomatology (OR 6.88, 95% CI 1.64&#x02013;28.90) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>). This study also found that benzodiazepine use was more common in those with anxiety (OR 3.77, 95% CI 2.52&#x02013;5.66) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>).</p><p>Notably, some factors were associated with reduced incidence of prescribing. A 2010 study found that patients prescribed benzodiazepines were less likely to have addiction issues than those who were not (OR 0.45, 95% CI 0.24&#x02013;0.87) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). This is supported by an earlier study from 2007, which found that benzodiazepine use was more common in those with fewer drug problems (OR 0.58, CI 95% 0.38&#x02013;0.88) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>). This supports the idea that drug addiction problems may lower prescribing of benzodiazepines.</p><p>Mood stabilisers, which are an ill&#x02010;defined medication class with significant overlap with antipsychotics and anticonvulsants, were found in a 2010 study to be more commonly utilised in patients with comorbid anxiety disorders (OR 2.95, 95% CI 1.04&#x02013;3.69) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). In this study, mood stabilisers were not defined by the author but were said to largely consist of topiramate (72% of these patients) and valproate (21%).</p><p>Overall, it appears that the presence of comorbid conditions, and perhaps anxiety in particular, is associated with increased levels of prescribing.</p></sec><sec id="pmh70014-sec-0014"><label>3.2.2</label><title>Age</title><p>Age was the second variable associated with prescribing regardless of medication class, though this conclusion is based on limited data. A 2021 study found that individuals were more likely to be prescribed medication, regardless of class, if they were older, with a mean age of 30.9 versus 27.3&#x02009;years (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0002) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>).</p><p>In particular, mood stabilisers&#x02014;which, as noted above, are a poorly defined group of medications&#x02014;(Malhi et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0021" ref-type="bibr">2018</xref>) were also found to be more commonly prescribed to older individuals, though specific statistics were not provided (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). Again, the authors did not define mood stabilisers, but they were said to largely consist of topiramate (72% of these patients) and valproate (21%).</p></sec><sec id="pmh70014-sec-0015"><label>3.2.3</label><title>Hospitalisation</title><p>Although not associated with general increases in prescribing, a single 2010 study found an increased likelihood of antipsychotic prescribing (OR 1.89, 95% CI 1.01&#x02013;3.54) in hospitalised patients (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). Additionally, the same study found mood stabiliser prescribing was also more common in those with a history of previous hospitalisation (OR 2.82, 95% CI 1.48&#x02013;5.36) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>).</p></sec><sec id="pmh70014-sec-0016"><label>3.2.4</label><title>Gender</title><p>Two studies found associations between gender and the prescribing of particular classes of medication.</p><p>Two separate studies conducted in Spain identified that antipsychotics were more frequently prescribed to male patients than to female patients (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>, <xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). The 2007 study identified the prescribing of antipsychotics as less likely in female patients (female OR 0.63, CI 95% 0.43&#x02013;09.4); the subsequent 2010 study concurred with this conclusion but did not provide specific statistics to support its findings.</p><p>The evidence around benzodiazepine usage and gender, however, appears conflicted. The 2007 study found that benzodiazepine use was also more common among male patients than female patients (female OR 0.63, 95% CI 0.42&#x02013;0.88) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>). This conclusion is contradicted by the 2010 study, which suggested, from a multivariate analysis, that benzodiazepines were more common among older female patients than male patients, though specific statistics were again not provided (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). This study, however, may have been biassed due to gender skew in the sample group, as 85.8% of the patients were female.</p></sec><sec id="pmh70014-sec-0017"><label>3.2.5</label><title>Presentation of Risk</title><p>At best, &#x02018;risk&#x02019; is ill&#x02010;defined as a term in clinical practice; however, two studies reported its correlation with prescribing. One study found antipsychotic prescribing more likely in patients assessed as presenting a risk to others (OR 2.07, 95% CI 1.39&#x02013;3.06) (Knappich et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0017" ref-type="bibr">2014</xref>), whereas a second study found that benzodiazepine use was less common among patients presenting fewer self&#x02010;care issues (OR 0.61, CI 96% 0.42&#x02013;0.88) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>).</p></sec><sec id="pmh70014-sec-0018"><label>3.2.6</label><title>Severity of Presentation</title><p>Only one study reported on associations between severity of presentation and prescribing. This 2010 study reported that higher impulsivity scores were associated with the use of antipsychotics (OR 1.77, 95% CI 1.09&#x02013;2.87) (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>), whereas the use of mood stabilisers was more common in those with less severe symptoms based on the Revised Diagnostic Interview for Borderlines (DIB&#x02010;R) scale (Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>). The DIB&#x02010;R scale (Zanarini et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0055" ref-type="bibr">1989</xref>) is a semistructured clinical interview used to diagnose BPD (Carcone et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0008" ref-type="bibr">2020</xref>).</p></sec></sec><sec id="pmh70014-sec-0019"><label>3.3</label><title>Thematic Factors</title><p>In addition to factors identified through the numerical analysis, the review identified two key themes associated with the prescribing of medication to patients with BPD: relationships and the care pathway.</p><sec id="pmh70014-sec-0020"><label>3.3.1</label><title>Relationships</title><p>Generally, across the identified literature, relationships were identified as an integral part of the prescribing of medication by both HCPs and patients.</p><p>In many countries, HCPs are taught that it is important to discuss treatment options carefully with patients and to ensure that patients are involved in the prescribing process (Say and Thomson&#x000a0;<xref rid="pmh70014-bib-0036" ref-type="bibr">2003</xref>). It is, therefore, logical that the patient would emerge as a central factor in the prescribing process. Nevertheless, it is important to note that many of the reported themes from the reviewed studies appear to imply negative connotations around this relationship &#x02010; denoted by the terms &#x02018;difficulty&#x02019; and &#x02018;challenging&#x02019;. &#x02018;Difficulty collaborating with patients&#x02019; was identified as a significant factor in the prescribing process by three of the four studies exploring the views of HCPs (Martean and Evans&#x000a0;<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>; Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>; Javed et&#x000a0;al. <xref rid="pmh70014-bib-0069" ref-type="bibr">2022</xref>) with comments such as</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0002"><p>troubled individuals. <named-content content-type="attribution">(Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0003"><p>Sometimes they will be really angry or upset if they are not getting what they want. <named-content content-type="attribution">(Martean and Evans&#x000a0;<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0004"><p>It just felt to me that the projection was so strong. <named-content content-type="attribution">(Martean and Evans&#x000a0;<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>)</named-content>
</p></disp-quote>
</p><p>These quotations suggest that some HCPs perceive patients with a diagnosis of BPD as challenging to engage with, particularly in the context of shared&#x02010;decision making.</p><p>The number of studies exploring patients' perspectives was limited to two studies (27 participants in total). Although this represents a limited data pool, the analysis showed that the HCP&#x02013;patient relationship is also a significant theme for patients. The theme of &#x02018;relationships&#x02019; differed for patients, focusing more on the &#x02018;need&#x02019; for a strong relationship and less on the relational challenges. Strong relationships were described using terms related to understanding, continuity of care, ease and degree of access to the HCP. The included studies identified subthemes of &#x02018;needing a relationship&#x02019; and the &#x02018;desire to confront authority&#x02019;.</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0005"><p>Back in the day, that sounds really silly, but you used to have one GP &#x02026;</p><p>I think you should be able to book an appointment with your doctor [GP] that lasts 15&#x02013;20&#x02009;min. <named-content content-type="attribution">(Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</named-content>
</p></disp-quote>
</p><p>The idea of &#x02018;need&#x02019; is prominent in both of the identified studies relating to patients' perspectives on BPD treatment. This &#x02018;need&#x02019; could be understood as patients' desire to be prescribed medication, referred to specialist service, or otherwise validated. It may also be part of the reason for the different focuses in referring to the HCP&#x02013;patient relationship for each party; patients need or seek something from HCPs, and therefore, this is a singularly important relationship for patients. For HCPs, however, the HCP&#x02013;patient relationship is one of many equally important relationships with other patients. This may be the cause of the perceived &#x02018;difficulty&#x02019; of treating BPD patients, indicated by comments such as</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0006"><p>Sometimes I've got a patient that I think is a bottomless pool of need. <named-content content-type="attribution">(Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0007"><p>People are people, they're not diagnoses. So, you'll keep on seeing them &#x02026; and you know that, yep, she's going to be needy and you hope that one day she'll say, &#x02018;yeah, today's a good day&#x02019;. <named-content content-type="attribution">(Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0008"><p>I've made an hour&#x02010;long appointment for a patient because she has so many problems, but then she didn't turn up. <named-content content-type="attribution">(Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</named-content>
</p></disp-quote>
</p></sec><sec id="pmh70014-sec-0021"><label>3.3.2</label><title>Care Pathway</title><p>HCPs do not act in a vacuum. In modern healthcare, they are one of a number of professionals engaging with patients. &#x02018;Integrated care&#x02019; or &#x02018;disease&#x02010;management&#x02019; pathways detail the fundamental steps in patient care and outline patients' expected journey through the healthcare system (Campbell et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0007" ref-type="bibr">1998</xref>). They are long processes that involve initial contact, follow&#x02010;up, referral to and from specialists and often a return to primary care (Schrijvers&#x000a0;<xref rid="pmh70014-bib-0037" ref-type="bibr">2009</xref>). It should, therefore, not come as a surprise that both HCPs and patients felt these pathways influenced patients' care and the prescribing of medication.</p><p>The review identified a recurrent theme of &#x02018;helplessness&#x02019; on the part of HCPs for a multitude of reasons, from lack of access of services, difficulties implementing national guidelines and feeling unable to provide care for patients with BPD.</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0009"><p>What can you offer to them? <named-content content-type="attribution">(Martean and Evans&#x000a0;<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0010"><p>We must have a consensus statement on what the evidence&#x02010;based interventions are that you can use in these conditions. Most diseases have a manual plan &#x02026;. <named-content content-type="attribution">(Wlodarczyk et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</named-content>
</p></disp-quote>
</p><p>The implication here is that, fundamentally, HCPs are unsure or unable to address the needs of the patient despite the presence of guidelines. Though it is not possible to determine from secondary analysis, it is worth considering how this &#x02018;helplessness&#x02019; plays into the HCP&#x02013;patient relationship.</p><p>Another key theme that emerged from the studies was that of &#x02018;uncertainty&#x02019; on the part of HCPs, particularly around the management of BPD. HCPs may find it difficult to manage &#x02018;uncertainty&#x02019;, as they might fear their patients' reactions and wish to avoid losing the trust of the patient; this may lead them to avoid expressing their uncertainty openly (van der Bles et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0052" ref-type="bibr">2019</xref>). Additionally, if they are &#x02018;uncertain&#x02019; of the care pathway, they may find it difficult to manage the patient's expectations.</p><p>Investigation into the perspective of patients with BPD found that, when attending appointments, patients often had specific expectations regarding their care and the healthcare system, such as being referred to specialist services or being prescribed specific medications (Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>) (Dickens et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0013" ref-type="bibr">2016</xref>). It is unclear why some patients have focussed expectations regarding pharmacological treatment, although some patient comments show clear expectations of benefits:</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0011"><p>The reason why I struggled as much as I did was that my GP never did want to put me on anything. <named-content content-type="attribution">(Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0012"><p>When you take the medications that are prescribed to you, it gives you energy, it clears your mind, it allows you to tolerate difficult feelings, distressing feelings, and it allows you to engage in some of the work that you do here, well, by being on medication. <named-content content-type="attribution">(Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</named-content>
</p></disp-quote>
</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0013"><p>Medication &#x02026; gets you to a point where you can be reached by other people. <named-content content-type="attribution">(Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</named-content>
</p></disp-quote>
</p><p>Moreover, a 2020 study into experiences in treating BPD reported that patients might become &#x02018;angry and exhibit self&#x02010;destructive behaviours when they feel neglected by their doctor&#x02019; (Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>). This indicates the importance of understanding patient expectations in any HCP&#x02010;patient relationship, highlighting a crossover between the two key themes identified across the studies.</p><p>
<disp-quote content-type="quotation" id="pmh70014-blkfxd-0014"><p>I went in and asked to talk to my psychiatrist that was supposed to be there and they were like &#x02018;He's not here today&#x02019; [&#x02026;] basically you are telling us that we are [s]upposed to pick and choose when we are gonna have a really bad day or really bad thoughts. <named-content content-type="attribution">(Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</named-content>
</p></disp-quote>
</p><p>Patients want to feel they can rely on or trust their care team, linking back to a relationship between the HCP and the patient.</p></sec></sec></sec><sec sec-type="discussion" id="pmh70014-sec-0022"><label>4</label><title>Discussion</title><p>Analysis of the included literature identified several demographic factors statistically associated with prescribing in BPD, such as comorbid conditions, older age and male gender, and two key themes were generated from the review of self&#x02010;reported factors associated with this prescribing: relationships and care pathways.</p><p>Although the primary studies identified were reasonably well&#x02010;designed, they are limited by two main issues. First, the relatively small sample size of a large proportion of the studies, particularly regarding patient and carer perspectives (total patients <italic toggle="yes">n</italic>&#x02009;=&#x02009;27, total informal carers <italic toggle="yes">n</italic>&#x02009;=&#x02009;0). Second, even those quantitative studies with larger sample sizes must be interpreted cautiously due to the observational nature of the identified studies. Many of these studies also relied on data from electronic health records, which could have introduced confounding variables due to unreported patient factors. Despite identifying potential factors associated with prescribing in BPD, due to these limitations, this synthesis represents only a starting point in further exploring prescribing decisions in BPD.</p><p>Interestingly, patients and HCPs have reported similar beliefs surrounding the management of BPD. Both parties identified &#x02018;relationships&#x02019; as integral to the prescribing process, though their beliefs around those relationships differed. What does emerge is the idea of a critical relationship between HCPs and their patients; the patient wants something and, to a lesser or greater degree, relies on the prescriber to obtain it.</p><p>This belief around the importance of, or need for, strong relationships has been reported in other studies about medication in patients with other serious mental illnesses (Green et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0014" ref-type="bibr">2008</xref>; Howe et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0015" ref-type="bibr">2023</xref>). Some of the relationships most valued by patients were those where the HCP showed care and treated clinical appointments &#x02018;like friendships&#x02019; (Green et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0014" ref-type="bibr">2008</xref>), reflecting that often, patients seek more than medical treatment; they seek a sense of empathy and mutual trust (Maidment et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0020" ref-type="bibr">2011</xref>) and understanding from HCPs (Kerasidou et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0016" ref-type="bibr">2021</xref>).</p><p>In this review, multiple instances were found of patients referring to the importance of medication, treatment and validation and expecting these from interactions with HCPs. Alongside this, multiple patients expressed frustration with limited access to treatment and therefore sought medication as an available treatment, due to limited access to longer term psychotherapy. Thus, prescribing can be seen as an attempt to address an unmet treatment need. This act, even if not entirely aligned with best practices, may serve to validate patients' experiences and convey a sense of acknowledgment and care.</p><p>A previous study that examined the experiences of patients with medication in BPD found that medication was seen positively by patients as they were able to exert control over prescribing decisions. This was particularly noted in patients who transitioned to specialist services where they were given more autonomy around medication (Rogers and Acton&#x000a0;<xref rid="pmh70014-bib-0034" ref-type="bibr">2012</xref>). The ability to exert influence may foster a sense of agency, which may improve outcomes in itself (Konstantinidou et&#x000a0;al. <xref rid="pmh70014-bib-0070" ref-type="bibr">2023</xref>). Moreover, active involvement in decision&#x02010;making may serve as evidence of mutual trust, thereby strengthening the patient&#x02013;HCP relationship. Therefore, given the importance of the prescriber&#x02013;patient relationship, the observed levels of prescribing may reflect an attempt to validate patients' needs, thereby reinforcing the relationship.</p><p>However, it is worth noting that being prescribed medication is not validating for all patients. In some cases, patients felt that their concerns or other needs were rather dismissed through the act of prescribing (Rogers and Acton&#x000a0;<xref rid="pmh70014-bib-0034" ref-type="bibr">2012</xref>; Tennant et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0049" ref-type="bibr">2023</xref>). It is important to note that the results detailing patients' perspectives here are based on only two qualitative studies, one of which focused predominantly on clozapine prescribing, therefore limiting any conclusions around patients' needs or wants and how these influence prescribing.</p><p>Studies in other cohorts of SMI patients have indicated HCP&#x02013;patient relationships can be improved through reducing &#x02018;mistrust&#x02019; (Howe et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0015" ref-type="bibr">2023</xref>). This concept is in line with a 2011 study employing focus groups on a number of mental health conditions in multiple mental health settings in England, which identified &#x02018;trust&#x02019; as a key and critical component in medication management (Maidment et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0020" ref-type="bibr">2011</xref>) and therefore the care pathway as a whole. Based on our findings, it may be that one factor in reducing mistrust may be in the open engagement of patients in prescribing decisions. The treatment of BPD may present a unique challenge in patient engagement however, as many of the diagnostic criteria for BPD are indicative of difficulties in forming and maintaining well&#x02010;functioning relationships, and thus, the nature of the HCP&#x02010;patient relationship may differ in BPD.</p><p>Additionally, although not an identified theme, it is important to acknowledge that the diagnosis of BPD is one that can result in specific patterns of stigmatising behaviour by some HCPs (Baker and Beazley&#x000a0;<xref rid="pmh70014-bib-0002" ref-type="bibr">2022</xref>), potentially adding further complications to a strained HCP&#x02010;patient relationship. This stigma will also need to be addressed when considering how a care pathway for BPD should be navigated, including prescribing decisions.</p><p>The idea that patients' expectations of being prescribed medication influence the decision to prescribe is neither a new phenomenon nor unique to BPD patients. A 2014 survey found that 55% of GPs felt under pressure to prescribe antibiotics. Furthermore, 44% of respondents disclosed that they had prescribed antibiotics to get a patient to leave the surgery, even if they did not believe them to be necessary (Cole&#x000a0;<xref rid="pmh70014-bib-0010" ref-type="bibr">2014</xref>).</p><p>Patients' influence on prescribing decisions is also not isolated to primary care. A 2011 study of prescribing decisions in hospitals found that &#x02018;pressure from patients, relatives, or carers was an uncomfortable influence on these hospital prescribers' prescribing decisions&#x02019;. This theme was reported by all specialities and grades of medical prescribers (Lewis and Tully&#x000a0;<xref rid="pmh70014-bib-0018" ref-type="bibr">2011</xref>).</p><p>When exploring the influence of the HCP&#x02013;patient relationship in prescribing, it is also important to acknowledge the desires of prescribers. This review found recurrent expressions of feelings of &#x02018;helplessness&#x02019; or &#x02018;frustration&#x02019; on the part of HCPs. These feelings may lead to a dynamic where the use of medication aims to manage not only patients' needs but also the prescriber's emotions. In essence the desire to help or resolve distress leads to prescribing, sometimes referred to as &#x02018;countertransference prescribing&#x02019; (Shapiro&#x02010;Thompson and Fineberg&#x000a0;<xref rid="pmh70014-bib-0039" ref-type="bibr">2022</xref>). This risk of countertransference prescribing may be exacerbated by the well&#x02010;documented challenges in accessing long&#x02010;term psychotherapy, recommended for the management of BPD, arising from a number of issues including a shortage of trained providers, stigmatisation and financial or commissioning barriers (Shapiro&#x02010;Thompson and Fineberg&#x000a0;<xref rid="pmh70014-bib-0039" ref-type="bibr">2022</xref>). HCPs are therefore left in a difficult position, where they are unable to follow guidance to offer psychotherapy and, feeling there are no alterative options, are left with prescribing.</p><p>The challenges around accessing treatment are entwined in the second emergent theme of the &#x02018;care pathway&#x02019;, along with the impacts of guidelines, referrals and specialist input on prescribing decisions raised by HCPs. Our findings identified several fundamental issues with the implementation of the guidelines. These include a lack of flexibility or discretion within the guidelines, limited access to long&#x02010;term psychological therapies, and the prevailing belief among HCPs and patients that the symptoms of BPD can be effectively managed through medication.</p><p>A 2018 review of 33 studies concluded, among other findings, that national guidance is fundamental to the prescribing process (Davari et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0012" ref-type="bibr">2018</xref>). As previously noted, the current preeminent guidelines advise against the use of medication in BPD, outside of comorbid conditions. Despite this clear position in the guidelines, repeated studies show high levels of prescribing in BPD (Bridler et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0005" ref-type="bibr">2015</xref>). A 2018 review suggests that guidelines that limit HCPs' discretion have &#x02018;doubtful implementation&#x02019; (Davari et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0012" ref-type="bibr">2018</xref>). In the case of BPD guidelines, HCPs' discretion is almost entirely removed, except for the treatment of comorbid conditions. This may be exacerbated by a lack of long&#x02010;term psychotherapy options and potential concerns around the strain on the HCP&#x02013;patient relationship if something is not offered (Shapiro&#x02010;Thompson and Fineberg&#x000a0;<xref rid="pmh70014-bib-0039" ref-type="bibr">2022</xref>; Soler et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0043" ref-type="bibr">2022</xref>). This may go some way to explaining the divergence from guidance in prescribing in BPD.</p><p>It may be particularly difficult for HCPs to navigate the care pathway for BPD patients when, regardless of the evidence base upon which guidelines are produced, as previously discussed some patients believe that medication has or will help them (Patel and Konstantinidou&#x000a0;<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>). As noted, the HCP&#x02013;patient relationship appears, at times, to be complicated by feelings of &#x02018;helplessness&#x02019; on the side of the HCP, who holds the perceived power. Therefore, in instances where medication is not prescribed, despite a patient's desire for it, an already complicated HCP&#x02013;patient relationship may be further strained, creating a gap between patient expectations and HCP duties to provide evidence&#x02010;based care. This gap may be further influenced by the quality of the underlying evidence base. A 2022 Cochrane review evaluated the evidence supporting trials as largely of low or very low quality and concluded with low certainty that medication may result in no difference in any primary outcome (Stoffers&#x02010;Winterling et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0044" ref-type="bibr">2022</xref>). However, the reviewers also reported inconclusive effects on secondary outcomes. These secondary outcomes include, but are not limited to, chronic feelings of emptiness, affective instability and anger. If it is the case that the outcomes measured in trials are not the most important to HCPs, this could help explain the observed dichotomy.</p><p>In cases where a decision to prescribe is made as part of the BPD care pathway, it is clear that there is an absence of guidance for HCPs. Without this fundamental influence, HCPs are likely to defer back to personal experience, senior colleagues' advice and perhaps guidance for other mental health conditions.</p><p>In terms of personal experience and senior colleagues' advice, there are indications that HCPs prescribe for patients with BPD based on symptoms (Crawford et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0011" ref-type="bibr">2011</xref>; Pascual et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>, <xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>). As such, it would appear that, at least in part, some HCPs do not agree with the advice in the guidelines and feel that individual symptoms can be treated. This may be due to HCPs' previous positive experiences of improvement in BPD patients prescribed medication.</p><p>It can therefore be hypothesised that in some cases, given the importance of guidelines, HCPs may resort to guidelines meant for other mental health conditions when treating the symptoms of BPD patients. As the use of medications is especially common in BPD patients with comorbid conditions, HCPs may treat comorbid conditions or particular subthreshold symptoms of BPD itself. Treating for particular symptoms assumes a shared aetiology for every presentation of a symptom, which may not be true. For example, instances of low mood in patients with BPD are not explicitly indicative of depression and therefore should not be treated as such.</p><p>Furthermore, in cases where pharmacological treatments of BPD prove ineffective, which is not unlikely given the limited evidence for their efficacy (Stoffers&#x02010;Winterling et&#x000a0;al.&#x000a0;<xref rid="pmh70014-bib-0044" ref-type="bibr">2022</xref>), HCPs may adjust or escalate treatment according to the guidelines in place for the symptom or perceived comorbid condition. This hypothesis may explain the levels of prescribing in the treatment of patients with BPD, as patients can fail to respond to the initial treatment, potentially leading HCPs to explore augmentation and multiple medications to address patients' symptoms in line with guidelines for other mental health conditions.</p><sec id="pmh70014-sec-0023"><label>4.1</label><title>Strengths and Limitations</title><p>This systematic review presents a comprehensive assessment of the current literature regarding the factors influencing prescribing in BPD patients. It identified 13 papers with diverse methodologies and populations, limiting the scope for statistical analysis. The included studies did, however, cover a range of practice settings, including primary, secondary and specialist care. The review did not include studies not published in English, and excluded pre&#x02010;1994 literature, which may have led to a loss of some available data. Despite some potential limitations, including the small number of primary studies and a limited review of grey literature, this review is the first&#x02014;to our knowledge&#x02014;to draw upon the available literature to explore factors influencing prescribing patterns in BPD. The key finding is the lack of data and limited research in this area.</p></sec><sec id="pmh70014-sec-0024"><label>4.2</label><title>Recommendations for Further Research</title><p>The review identified a lack of research into the factors influencing prescribing in patients with BPD. Only two studies examining patient perspectives, which included 26 individuals, were found. Replication studies of the existing literature, especially qualitative interviews with patients, would support the robustness of existing findings.</p><p>No studies exploring informal carers' views were identified, possibly due to the limited focus on patient perspectives in the existing literature. Further studies exploring the opinions of carers would also add value.</p><p>Beyond this, further research is needed to explore how the relationship between professionals and patients, care pathways and patient demographics can impact prescribing. In particular, further exploration and investigation of targeted interventions impacting the identified themes and any resulting changes in prescribing levels would be of particular interest and value.</p><p>Furthermore, research aimed at identifying the trial outcomes that are most valued by patients and HCPs could also be beneficial. Such studies can provide critical insights into shared priorities, which are important for understanding prescribing decisions and ensuring that future trials align more closely with the needs and expectations of both patients and HCPs.</p><p>By highlighting the gaps in current research, this review provides a starting point for future investigations and interventions.</p></sec></sec><sec sec-type="conclusions" id="pmh70014-sec-0025"><label>5</label><title>Conclusion</title><p>Findings from this review identify demographics that are potential influences on the prescribing of medication in BPD patients, including comorbidity, age and presenting symptoms. One key conclusion is the limited research on factors affecting prescribing in this population.</p><p>Furthermore, the review indicates that the themes of the HCP&#x02013;patient relationship, identified by both HCPs and patients, and the care pathway are also important influences on the prescribing process. Within both themes, some potential challenges have been suggested, particularly &#x02018;helplessness&#x02019; on the part of HCPs, the influence of guidelines and patients' expectations.</p><p>Addressing and strengthening the HCP&#x02013;patient relationship seems integral to improving prescribing. Although more research is required, these results indicate a promising starting point for future research and interventions.</p><p>There are indications that HCPs may be prescribing in BPD for symptoms they believe can be treated; to maintain therapeutic relationships; due to countertransference; and due to a lack of accessible long&#x02010;term psychotherapy. However, this is based on a small number of studies, only two of which explored patients' opinions and none examining the perspectives of informal carers or family members.</p><p>Future research should seek to explore this further to provide HCPs with insight into the factors at play in prescribing for BPD patients. Only through a better understanding of how people arrive at prescribing decisions can unnecessary prescribing be avoided or corrected.</p></sec><sec id="pmh70014-sec-0026"><title>Author Contributions</title><p>JC conceived of the presented idea. JC, IM and MJ developed the theory and methodology. The searches, study selection and data extraction were conducted by JC and SJ. IM and MJ encouraged JC and SJ in the review and subsequent analysis and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.</p></sec><sec id="pmh70014-sec-0027"><title>Ethics Statement</title><p>The submitted manuscript represents a Systematic Review and was exempt from the ethical approval process at the University of Bath, as it only involved secondary analysis of anonymised data.</p></sec><sec sec-type="COI-statement" id="pmh70014-sec-0028"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><sec sec-type="data-availability" id="pmh70014-sec-0030"><title>Data Availability Statement</title><p>Data availability is not applicable to this article, as no new data were created or analysed in this study.</p></sec><ref-list content-type="cited-references" id="pmh70014-bibl-0001"><title>References</title><ref id="pmh70014-bib-0001"><mixed-citation publication-type="book" id="pmh70014-cit-0001">
<string-name>
<surname>Abel</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Taylor</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Duncan</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>McConnell</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Kerwin</surname>
</string-name>. <year>2018</year>. <source>The Maudsley Prescribing Guidelines</source>. <publisher-name>Wiley Blackwell</publisher-name>.</mixed-citation></ref><ref id="pmh70014-bib-0002"><mixed-citation publication-type="journal" id="pmh70014-cit-0002">
<string-name>
<surname>Baker</surname>, <given-names>J.</given-names>
</string-name>, and <string-name>
<given-names>P. I.</given-names>
<surname>Beazley</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>Judging Personality Disorder: A Systematic Review of Clinician Attitudes and Responses to Borderline Personality Disorder</article-title>.&#x0201d; <source>Journal of Psychiatric Practice</source>
<volume>28</volume>, no. <issue>4</issue>: <fpage>275</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1097/PRA.0000000000000642</pub-id>.<pub-id pub-id-type="pmid">35797685</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0003"><mixed-citation publication-type="journal" id="pmh70014-cit-0003">
<string-name>
<surname>Bohus</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Stoffers&#x02010;Winterling</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Sharp</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Krause&#x02010;Utz</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Schmahl</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Lieb</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Borderline Personality Disorder</article-title>.&#x0201d; <source>Lancet</source>
<volume>398</volume>, no. <issue>10310</issue>: <fpage>1528</fpage>&#x02013;<lpage>1540</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00476-1</pub-id>.<pub-id pub-id-type="pmid">34688371</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0004"><mixed-citation publication-type="journal" id="pmh70014-cit-0004">
<string-name>
<surname>Botham</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Simpson</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>McCrone</surname>
</string-name>. <year>2024</year>. &#x0201c;<article-title>Mental Health Service use and Costs Associated With Complex Emotional Needs and a Diagnosis of Personality Disorder: Analysis of Routine Data</article-title>.&#x0201d; <source>BJPsych Bulletin</source>
<volume>48</volume>, no. <issue>2</issue>: <fpage>85</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1192/bjb.2023.41</pub-id>.<pub-id pub-id-type="pmid">37310185</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0005"><mixed-citation publication-type="journal" id="pmh70014-cit-0005">
<string-name>
<surname>Bridler</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>H&#x000e4;berle</surname>
</string-name>, <string-name>
<given-names>S. T.</given-names>
<surname>M&#x000fc;ller</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Psychopharmacological Treatment of 2195 In&#x02010;Patients With Borderline Personality Disorder: A Comparison With Other Psychiatric Disorders</article-title>.&#x0201d; <source>European Neuropsychopharmacology</source>
<volume>25</volume>, no. <issue>6</issue>: <fpage>763</fpage>&#x02013;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1016/J.EURONEURO.2015.03.017</pub-id>.<pub-id pub-id-type="pmid">25907249</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0006"><mixed-citation publication-type="journal" id="pmh70014-cit-0006">
<string-name>
<surname>Byrne</surname>, <given-names>D.</given-names>
</string-name>
<year>2022</year>. &#x0201c;<article-title>A Worked Example of Braun and Clarke's Approach to Reflexive Thematic Analysis</article-title>.&#x0201d; <source>Quality &#x00026; Quantity</source>
<volume>56</volume>, no. <issue>3</issue>: <fpage>1391</fpage>&#x02013;<lpage>1412</lpage>. <pub-id pub-id-type="doi">10.1007/s11135-021-01182-y</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0007"><mixed-citation publication-type="journal" id="pmh70014-cit-0007">
<string-name>
<surname>Campbell</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Hotchkiss</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Bradshaw</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Porteous</surname>
</string-name>. <year>1998</year>. &#x0201c;<article-title>Integrated Care Pathways BMJ</article-title>.&#x0201d; <volume>316</volume>, no. <issue>7125</issue>: <fpage>133</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1136/BMJ.316.7125.133</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0008"><mixed-citation publication-type="book" id="pmh70014-cit-0008">
<string-name>
<surname>Carcone</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Zanarini</surname>
</string-name>, and <string-name>
<given-names>A. C.</given-names>
<surname>Ruocco</surname>
</string-name>. <year>2020</year>. &#x0201c;<part-title>Revised Diagnostic Interview for Borderlines</part-title>.&#x0201d; In <source>Encyclopedia of Personality and Individual Differences</source>, edited by <person-group person-group-type="editor">
<string-name>
<given-names>V.</given-names>
<surname>Zeigler&#x02010;Hill</surname>
</string-name>
</person-group> and <person-group person-group-type="editor">
<string-name>
<given-names>T. K.</given-names>
<surname>Shackelford</surname>
</string-name>
</person-group>, <fpage>4458</fpage>&#x02013;<lpage>4460</lpage>. <publisher-name>Springer International Publishing</publisher-name>. <pub-id pub-id-type="doi">10.1007/978-3-319-24612-3_71</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0009"><mixed-citation publication-type="journal" id="pmh70014-cit-0009">
<string-name>
<surname>Coid</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Tyrer</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Roberts</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Ullrich</surname>
</string-name>. <year>2006</year>. &#x0201c;<article-title>Prevalence and Correlates of Personality Disorder in Great Britain</article-title>.&#x0201d; <source>British Journal of Psychiatry</source>
<volume>188</volume>, no. <issue>5</issue>: <fpage>423</fpage>&#x02013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.188.5.423</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0010"><mixed-citation publication-type="journal" id="pmh70014-cit-0010">
<string-name>
<surname>Cole</surname>, <given-names>A.</given-names>
</string-name>
<year>2014</year>. &#x0201c;<article-title>GPs Feel Pressurised to Prescribe Unnecessary Antibiotics, Survey Finds</article-title>.&#x0201d; <source>BMJ: British Medical Journal</source>
<volume>349</volume>: <elocation-id>g5238</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.g5238</pub-id>.<pub-id pub-id-type="pmid">25143516</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0011"><mixed-citation publication-type="journal" id="pmh70014-cit-0011">
<string-name>
<surname>Crawford</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kakad</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Rendel</surname>
</string-name>, et&#x000a0;al. <year>2011</year>. &#x0201c;<article-title>Medication Prescribed to People With Personality Disorder: The Influence of Patient Factors and Treatment Setting</article-title>.&#x0201d; <source>Acta Psychiatrica Scandinavica</source>
<volume>124</volume>, no. <issue>5</issue>: <fpage>396</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1111/j.16000447.2011.01728.x</pub-id>.<pub-id pub-id-type="pmid">21707555</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0012"><mixed-citation publication-type="journal" id="pmh70014-cit-0012">
<string-name>
<surname>Davari</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Khorasani</surname>
</string-name>, and <string-name>
<given-names>B. M.</given-names>
<surname>Tigabu</surname>
</string-name>. <year>2018</year>. &#x0201c;<article-title>Factors Influencing Prescribing Decisions of Physicians: A Review</article-title>.&#x0201d; <source>Ethiopian Journal of Health Sciences</source>
<volume>28</volume>, no. <issue>6</issue>: <fpage>795</fpage>&#x02013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.4314/ejhs.v28i6.15</pub-id>.<pub-id pub-id-type="pmid">30607097</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0013"><mixed-citation publication-type="journal" id="pmh70014-cit-0013">
<string-name>
<surname>Dickens</surname>, <given-names>G. L.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Frogley</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Mason</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Anagnostakis</surname>
</string-name>, and <string-name>
<given-names>M. M.</given-names>
<surname>Picchioni</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Experiences of Women in Secure Care who Have Been Prescribed Clozapine for Borderline Personality Disorder</article-title>.&#x0201d; <source>Borderline Personality Disorder and Emotion Dysregulation</source>
<volume>3</volume>, no. <issue>1</issue>: <fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/s40479-016-0049-x</pub-id>.<pub-id pub-id-type="pmid">27761261</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0014"><mixed-citation publication-type="journal" id="pmh70014-cit-0014">
<string-name>
<surname>Green</surname>, <given-names>C. A.</given-names>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Polen</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Janoff</surname>
</string-name>, et&#x000a0;al. <year>2008</year>. &#x0201c;<article-title>Understanding how Clinician&#x02010;Patient Relationships and Relational Continuity of Care Affect Recovery From Serious Mental Illness: STARS Study Results</article-title>.&#x0201d; <source>Psychiatric Rehabilitation Journal</source>
<volume>32</volume>, no. <issue>1</issue>: <fpage>9</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.2975/32.1.2008.9.22</pub-id>.<pub-id pub-id-type="pmid">18614445</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0015"><mixed-citation publication-type="journal" id="pmh70014-cit-0015">
<string-name>
<surname>Howe</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Macphee</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Duddy</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>A Realist Review of Medication Optimisation of Community Dwelling Service Users With Serious Mental Illness</article-title>.&#x0201d; <source>BMJ Quality and Safety</source>
<volume>34</volume>, no. <issue>1</issue>: <fpage>40</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1136/bmjqs-2023016615</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0069"><mixed-citation publication-type="journal" id="pmh70014-cit-0069">
<string-name>
<surname>Javed</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Javed</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Memon</surname>
</string-name>, and <string-name>
<given-names>O.</given-names>
<surname>Okopi</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>Prescribing for Emotionally Unstable Personality Disorder: Clinicians&#x02019; Views</article-title>.&#x0201d; <source>Progress in Neurology and Psychiatry</source>
<volume>26</volume>: <fpage>31</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/pnp.759</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0016"><mixed-citation publication-type="journal" id="pmh70014-cit-0016">
<string-name>
<surname>Kerasidou</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>B&#x000e6;r&#x000f8;e</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Berger</surname>
</string-name>, and <string-name>
<given-names>A. E. C.</given-names>
<surname>Brown</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>The Need for Empathetic Healthcare Systems</article-title>.&#x0201d; <source>Journal of Medical Ethics</source>
<volume>47</volume>, no. <issue>12</issue>: <elocation-id>e27</elocation-id>. <pub-id pub-id-type="doi">10.1136/medethics-2019105921</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0017"><mixed-citation publication-type="journal" id="pmh70014-cit-0017">
<string-name>
<surname>Knappich</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>H&#x000f6;rz&#x02010;Sagstetter</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Schwerth&#x000f6;ffer</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Leucht</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Rentrop</surname>
</string-name>. <year>2014</year>. &#x0201c;<article-title>Pharmacotherapy in the Treatment of Patients With Borderline Personality Disorder: Results of a Survey Among Psychiatrists in Private Practices</article-title>.&#x0201d; <source>International Clinical Psychopharmacology</source>
<volume>29</volume>, no. <issue>4</issue>: <fpage>224</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1097/YIC.0000000000000021</pub-id>.<pub-id pub-id-type="pmid">24896541</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0070"><mixed-citation publication-type="journal" id="pmh70014-cit-0070">
<string-name>
<surname>Konstantinidou</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Chartonas</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Rogalski</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Lee</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Will This Tablet Make Me Happy Again? The Contribution of Relational Prescribing in Providing a Pragmatic and Psychodynamic Framework for Prescribers</article-title>.&#x0201d; <source>BJPsych Advances</source>
<volume>29</volume>, no. <issue>4</issue>: <fpage>265</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1192/bja.2022.43</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0018"><mixed-citation publication-type="journal" id="pmh70014-cit-0018">
<string-name>
<surname>Lewis</surname>, <given-names>P. J.</given-names>
</string-name>, and <string-name>
<given-names>M. P.</given-names>
<surname>Tully</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>The Discomfort Caused by Patient Pressure on the Prescribing Decisions of Hospital Prescribers</article-title>.&#x0201d; <source>Research in Social and Administrative Pharmacy</source>
<volume>7</volume>, no. <issue>1</issue>: <fpage>4</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/J.SAPHARM.2010.02.002</pub-id>.<pub-id pub-id-type="pmid">21397877</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0019"><mixed-citation publication-type="journal" id="pmh70014-cit-0019">
<string-name>
<surname>Lieb</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>V&#x000f6;llm</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>R&#x000fc;cker</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Timmer</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Stoffers</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>Pharmacotherapy for Borderline Personality Disorder: Cochrane Systematic Review of Randomised Trials</article-title>.&#x0201d; <source>British Journal of Psychiatry: The Journal of Mental Science</source>
<volume>196</volume>, no. <issue>1</issue>: <fpage>4</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1192/BJP.BP.108.062984</pub-id>.<pub-id pub-id-type="pmid">20044651</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0020"><mixed-citation publication-type="journal" id="pmh70014-cit-0020">
<string-name>
<surname>Maidment</surname>, <given-names>I. D.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Brown</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Calnan</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>An Exploratory Study of the Role of Trust in Medication Management Within Mental Health Services</article-title>.&#x0201d; <source>International Journal of Clinical Pharmacy</source>
<volume>33</volume>, no. <issue>4</issue>: <fpage>614</fpage>&#x02013;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1007/s11096-011-9510-5</pub-id>.<pub-id pub-id-type="pmid">21541701</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0021"><mixed-citation publication-type="journal" id="pmh70014-cit-0021">
<string-name>
<surname>Malhi</surname>, <given-names>G. S.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Porter</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Irwin</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Defining a Mood Stabiliser: Novel Framework for Research and Clinical Practice</article-title>.&#x0201d; <source>BJPsych Open</source>
<volume>4</volume>, no. <issue>4</issue>: <fpage>278</fpage>&#x02013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1192/BJO.2018.36</pub-id>.<pub-id pub-id-type="pmid">30083379</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0022"><mixed-citation publication-type="journal" id="pmh70014-cit-0022">
<string-name>
<surname>Martean</surname>, <given-names>L.</given-names>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Evans</surname>
</string-name>. <year>2014</year>. &#x0201c;<article-title>Prescribing for Personality Disorder: Qualitative Study of Interviews With General and Forensic Consultant Psychiatrists</article-title>.&#x0201d; <source>Psychiatric Bulletin</source>
<volume>38</volume>, no. <issue>3</issue>: <fpage>116</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1192/pb.bp.113.044081</pub-id>.<pub-id pub-id-type="pmid">25237521</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0023"><mixed-citation publication-type="book" id="pmh70014-cit-0023">
<string-name>
<surname>McCrone</surname>, <given-names>P. R.</given-names>
</string-name>, and <collab collab-type="authors">King's Fund</collab>
. <year>2008</year>. <source>Paying the Price : The Cost of Mental Health Care in England to 2026</source>. <publisher-name>King's Fund</publisher-name>.</mixed-citation></ref><ref id="pmh70014-bib-0024"><mixed-citation publication-type="journal" id="pmh70014-cit-0024">
<string-name>
<surname>Methley</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Campbell</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Chew&#x02010;Graham</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>McNally</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Cheraghi&#x02010;Sohi</surname>
</string-name>. <year>2014</year>. &#x0201c;<article-title>PICO, PICOS and SPIDER: A Comparison Study of Specificity and Sensitivity in Three Search Tools for Qualitative Systematic Reviews</article-title>.&#x0201d; <source>BMC Health Services Research</source>
<volume>14</volume>, no. <issue>1</issue>: <elocation-id>579</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12913-014-0579-0</pub-id>.<pub-id pub-id-type="pmid">25413154</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0067"><mixed-citation publication-type="journal" id="pmh70014-cit-0067">
<string-name>
<surname>Mirhaj Mohammadabadi</surname>, <given-names>M. S.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Mohammadsadeghi</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Eftekhar Adrebili</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Factors Associated With Pharmacological and Psychotherapy Treatments Adherence in Patients With Borderline Personality Disorder</article-title>.&#x0201d; <source>Frontiers in Psychiatry</source>
<volume>13</volume>: <elocation-id>1056050</elocation-id>. <pub-id pub-id-type="doi">10.3389/fpsyt.2022.1056050</pub-id>.<pub-id pub-id-type="pmid">36582255</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0025"><mixed-citation publication-type="miscellaneous" id="pmh70014-cit-0025">
<string-name>
<surname>Nha Hong</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Pluye</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>F&#x000e0;bregues</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Mixed Methods Appraisal Tool (MMAT)</article-title>.&#x0201d; <ext-link xlink:href="http://mixedmethodsappraisaltoolpublic.pbworks.com/" ext-link-type="uri">http://mixedmethodsappraisaltoolpublic.pbworks.com/</ext-link>.</mixed-citation></ref><ref id="pmh70014-bib-0071"><mixed-citation publication-type="journal" id="pmh70014-cit-0071">
<string-name>
<surname>Noyes</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Booth</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Moore</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Flemming</surname>
</string-name>, <string-name>
<given-names>&#x000d6;.</given-names>
<surname>Tun&#x000e7;alp</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Shakibazadeh</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Synthesising Quantitative and Qualitative Evidence to Inform Guidelines on Complex Interventions: Clarifying the Purposes, Designs and Outlining Some Methods</article-title>.&#x0201d; <source>BMJ Global Health</source>
<volume>4</volume>, no. <issue>Suppl 1</issue>: <elocation-id>e000893</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjgh-2018-000893</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0027"><mixed-citation publication-type="journal" id="pmh70014-cit-0027">
<string-name>
<surname>Page</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>McKenzie</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Bossuyt</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title>.&#x0201d; <source>BMJ</source>
<volume>372</volume>: <elocation-id>n71</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>.<pub-id pub-id-type="pmid">33782057</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0028"><mixed-citation publication-type="journal" id="pmh70014-cit-0028">
<string-name>
<surname>Pascual</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>C&#x000f3;rcoles</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Casta&#x000f1;o</surname>
</string-name>, et&#x000a0;al. <year>2007</year>. &#x0201c;<article-title>Hospitalization and Pharmacotherapy for Borderline Personality Disorder in a Psychiatric Emergency Service</article-title>.&#x0201d; <source>Psychiatric Services</source>
<volume>58</volume>, no. <issue>9</issue>: <fpage>1199</fpage>&#x02013;<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1176/ps.2007.58.9.1199</pub-id>.<pub-id pub-id-type="pmid">17766566</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0029"><mixed-citation publication-type="journal" id="pmh70014-cit-0029">
<string-name>
<surname>Pascual</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mart&#x000ed;n&#x02010;Blanco</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Soler</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Twenty&#x02010;Year Trends in the Psychopharmacological Treatment of Outpatients With Borderline Personality Disorder: A Cross&#x02010;Sectional Naturalistic Study in Spain</article-title>.&#x0201d; <source>CNS Drugs</source>
<volume>35</volume>, no. <issue>9</issue>: <fpage>1023</fpage>&#x02013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-021-00852-7</pub-id>.<pub-id pub-id-type="pmid">34370282</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0030"><mixed-citation publication-type="journal" id="pmh70014-cit-0030">
<string-name>
<surname>Pascual</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mart&#x000ed;n&#x02010;Blanco</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Soler</surname>
</string-name>, et&#x000a0;al. <year>2010</year>. &#x0201c;<article-title>A Naturalistic Study of Changes in Pharmacological Prescription for Borderline Personality Disorder in Clinical Practice: From APA to NICE Guidelines</article-title>.&#x0201d; <source>International Clinical Psychopharmacology</source>
<volume>25</volume>, no. <issue>6</issue>: <fpage>349</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1097/YIC.0b013e32833e23ed</pub-id>.<pub-id pub-id-type="pmid">20838221</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0031"><mixed-citation publication-type="journal" id="pmh70014-cit-0031">
<string-name>
<surname>Patel</surname>, <given-names>D.</given-names>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Konstantinidou</surname>
</string-name>. <year>2020</year>. &#x0201c;<article-title>Prescribing in Personality Disorder: Patients' Perspectives on Their Encounters With GPs and Psychiatrists</article-title>.&#x0201d; <source>Family Medicine and Community Health</source>
<volume>8</volume>, no. <issue>4</issue>: <elocation-id>e000458</elocation-id>. <pub-id pub-id-type="doi">10.1136/fmch-2020000458</pub-id>.<pub-id pub-id-type="pmid">32958520</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0032"><mixed-citation publication-type="journal" id="pmh70014-cit-0032">
<string-name>
<surname>Paton</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Crawford</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bhatti</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Patel</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Barnes</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>The use of Psychotropic Medication in Patients With Emotionally Unstable Personality Disorder Under the Care of UK Mental Health Services</article-title>.&#x0201d; <source>Journal of Clinical Psychiatry</source>
<volume>76</volume>: <fpage>e512</fpage>&#x02013;<lpage>e518</lpage>. <pub-id pub-id-type="doi">10.4088/JCP.14m09228</pub-id>.<pub-id pub-id-type="pmid">25919844</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0033"><mixed-citation publication-type="miscellaneous" id="pmh70014-cit-0033">
<collab collab-type="authors">POMH&#x02010;UK</collab>
. <year>2014</year>. &#x0201c;<article-title>Prescribing Observatory for Mental Health</article-title>.&#x0201d; <ext-link xlink:href="http://www.rcpsych.ac.uk/improving-care/ccqi/national-clinical-audits/pomh-uk" ext-link-type="uri">www.rcpsych.ac.uk/improving&#x02010;care/ccqi/national&#x02010;clinical&#x02010;audits/pomh&#x02010;uk</ext-link>.</mixed-citation></ref><ref id="pmh70014-bib-0034"><mixed-citation publication-type="journal" id="pmh70014-cit-0034">
<string-name>
<surname>Rogers</surname>, <given-names>B.</given-names>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Acton</surname>
</string-name>. <year>2012</year>. &#x0201c;<article-title>&#x0201c;I Think We're All Guinea Pigs Really&#x0201d;: A Qualitative Study of Medication and Borderline Personality Disorder</article-title>.&#x0201d; <source>Journal of Psychiatric and Mental Health Nursing</source>
<volume>19</volume>, no. <issue>4</issue>: <fpage>341</fpage>&#x02013;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1111/J.13652850.2011.01800.X</pub-id>.<pub-id pub-id-type="pmid">22070628</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0035"><mixed-citation publication-type="miscellaneous" id="pmh70014-cit-0035">
<string-name>
<surname>Ryan</surname>, <given-names>R.</given-names>
</string-name>
<year>2016</year>. &#x0201c;<article-title>Cochrane Consumers and Communication Review Group: Data Synthesis and Analysis</article-title>.&#x0201d;</mixed-citation></ref><ref id="pmh70014-bib-0036"><mixed-citation publication-type="journal" id="pmh70014-cit-0036">
<string-name>
<surname>Say</surname>, <given-names>R. E.</given-names>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Thomson</surname>
</string-name>. <year>2003</year>. &#x0201c;<article-title>The Importance of Patient Preferences in Treatment Decisions&#x02014;Challenges for Doctors</article-title>.&#x0201d; <source>BMJ</source>
<volume>327</volume>, no. <issue>7414</issue>: <fpage>542</fpage>&#x02013;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.327.7414.542</pub-id>.<pub-id pub-id-type="pmid">12958116</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0037"><mixed-citation publication-type="journal" id="pmh70014-cit-0037">
<string-name>
<surname>Schrijvers</surname>, <given-names>G.</given-names>
</string-name>
<year>2009</year>. &#x0201c;<article-title>Disease Management: A Proposal for a new Definition</article-title>.&#x0201d; <source>International Journal of Integrated Care</source>
<volume>9</volume>, no. <issue>1</issue>: <elocation-id>e06</elocation-id>. <pub-id pub-id-type="doi">10.5334/IJIC.301</pub-id>.<pub-id pub-id-type="pmid">19340329</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0068"><mixed-citation publication-type="journal" id="pmh70014-cit-0068">
<string-name>
<surname>Schulkens</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Bergs</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ingenhoven</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Rosowsky</surname>
</string-name>, <string-name>
<given-names>S. V.</given-names>
<surname>Alphen</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Sobczak</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Selective Serotonin Reuptake&#x02010;Inhibitors for Symptom&#x02010;Based Treatment of Borderline Personality Disorders in Older Adults: An International Delphi Study</article-title>.&#x0201d; <source>Clinical Psychopharmacology and Neuroscience</source>
<volume>19</volume>, no. <issue>1</issue>: <fpage>53</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.9758/cpn.2021.19.1.53</pub-id>.<pub-id pub-id-type="pmid">33508788</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0038"><mixed-citation publication-type="journal" id="pmh70014-cit-0038">
<string-name>
<surname>Schumock</surname>, <given-names>G. T.</given-names>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Walton</surname>
</string-name>, <string-name>
<given-names>H. Y.</given-names>
<surname>Park</surname>
</string-name>, et&#x000a0;al. <year>2004</year>. &#x0201c;<article-title>Factors That Influence Prescribing Decisions</article-title>.&#x0201d; <source>Annals of Pharmacotherapy</source>
<volume>38</volume>, no. <issue>4</issue>: <fpage>557</fpage>&#x02013;<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1345/APH.1D390</pub-id>.<pub-id pub-id-type="pmid">14966259</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0039"><mixed-citation publication-type="journal" id="pmh70014-cit-0039">
<string-name>
<surname>Shapiro&#x02010;Thompson</surname>, <given-names>R.</given-names>
</string-name>, and <string-name>
<given-names>S. K.</given-names>
<surname>Fineberg</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors</article-title>.&#x0201d; <source>Current Treatment Options in Psychiatry</source>
<volume>9</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/S40501-021-00255-X</pub-id>.<pub-id pub-id-type="pmid">36185615</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0040"><mixed-citation publication-type="journal" id="pmh70014-cit-0040">
<string-name>
<surname>Shin</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>H. S.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>B. C.</given-names>
<surname>Lee</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>The Prevalence and Clinical Characteristics of Borderline Personality Disorder in South Korea Using National Health Insurance Service Customized Database</article-title>.&#x0201d; <source>Yonsei Medical Journal</source>
<volume>64</volume>, no. <issue>9</issue>: <fpage>566</fpage>&#x02013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.3349/ymj.2023.0071</pub-id>.<pub-id pub-id-type="pmid">37634633</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0041"><mixed-citation publication-type="book" id="pmh70014-cit-0041">
<string-name>
<surname>Silk</surname>, <given-names>K. R.</given-names>
</string-name>
<year>2002</year>. <source>Current Psychiatry</source>. Vol. <volume>1</volume>. <edition>11th ed.</edition>
<publisher-name>Springer Science</publisher-name>. <ext-link xlink:href="https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/0111_Borderline.pdf" ext-link-type="uri">https://cdn.mdedge.com/files/s3fs&#x02010;public/Document/September&#x02010;2017/0111_Borderline.pdf</ext-link>.</mixed-citation></ref><ref id="pmh70014-bib-0042"><mixed-citation publication-type="journal" id="pmh70014-cit-0042">
<string-name>
<surname>Silk</surname>, <given-names>K. R.</given-names>
</string-name>
<year>2015</year>. &#x0201c;<article-title>Management and Effectiveness of Psychopharmacology in Emotionally Unstable and Borderline Personality Disorder</article-title>.&#x0201d; <source>Journal of Clinical Psychiatry</source>
<volume>76</volume>, no. <issue>4</issue>: <elocation-id>e524&#x02013;e525</elocation-id>. <pub-id pub-id-type="doi">10.4088/JCP.14com09534</pub-id>.<pub-id pub-id-type="pmid">25919848</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0043"><mixed-citation publication-type="journal" id="pmh70014-cit-0043">
<string-name>
<surname>Soler</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Casellas&#x02010;Pujol</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Fern&#x000e1;ndez&#x02010;Felipe</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mart&#x000ed;n&#x02010;Blanco</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Almenta</surname>
</string-name>, and <string-name>
<given-names>J. C.</given-names>
<surname>Pascual</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>&#x0201c;Skills for Pills&#x0201d;: The Dialectical&#x02010;Behavioural Therapy Skills Training Reduces Polypharmacy in Borderline Personality Disorder</article-title>.&#x0201d; <source>Acta Psychiatrica Scandinavica</source>
<volume>145</volume>, no. <issue>4</issue>: <fpage>332</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1111/ACPS.13403</pub-id>.<pub-id pub-id-type="pmid">35088405</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0044"><mixed-citation publication-type="journal" id="pmh70014-cit-0044">
<string-name>
<surname>Stoffers&#x02010;Winterling</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<given-names>O. J.</given-names>
<surname>Storeb&#x000f8;</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Pereira Ribeiro</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Pharmacological Interventions for People With Borderline Personality Disorder</article-title>.&#x0201d; <source>Cochrane Database of Systematic Reviews</source>
<volume>2022</volume>, no. <issue>11</issue>: <elocation-id>CD012956</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD012956.pub2</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0045"><mixed-citation publication-type="journal" id="pmh70014-cit-0045">
<string-name>
<surname>Sukhera</surname>, <given-names>J.</given-names>
</string-name>
<year>2022</year>. &#x0201c;<article-title>Narrative Reviews: Flexible, Rigorous, and Practical</article-title>.&#x0201d; <source>Journal of Graduate Medical Education</source>
<volume>14</volume>, no. <issue>4</issue>: <fpage>414</fpage>&#x02013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.4300/JGME-D-2200480.1</pub-id>.<pub-id pub-id-type="pmid">35991099</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0046"><mixed-citation publication-type="journal" id="pmh70014-cit-0046">
<string-name>
<surname>Tedesco</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<given-names>N. J. S.</given-names>
<surname>Day</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Lucas</surname>
</string-name>, and <string-name>
<given-names>B. F. S.</given-names>
<surname>Grenyer</surname>
</string-name>. <year>2024</year>. &#x0201c;<article-title>Diagnosing Borderline Personality Disorder: Reports and Recommendations From People With Lived Experience</article-title>.&#x0201d; <source>Personality and Mental Health</source>
<volume>18</volume>, no. <issue>2</issue>: <fpage>107</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1002/PMH.1599</pub-id>.<pub-id pub-id-type="pmid">37997227</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0047"><mixed-citation publication-type="journal" id="pmh70014-cit-0047">
<string-name>
<surname>Temes</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Frankenburg</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Fitzmaurice</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Zanarini</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Deaths by Suicide and Other Causes Among Patients With Borderline Personality Disorder and Personality&#x02010;Disordered Comparison Subjects Over 24 Years of Prospective Follow&#x02010;Up</article-title>.&#x0201d; <source>Journal of Clinical Psychiatry</source>
<volume>80</volume>, no. <issue>1</issue>: <elocation-id>4039</elocation-id>. <pub-id pub-id-type="doi">10.4088/JCP.18m12436</pub-id>.</mixed-citation></ref><ref id="pmh70014-bib-0048"><mixed-citation publication-type="journal" id="pmh70014-cit-0048">
<string-name>
<surname>ten Have</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Verheul</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kaasenbrood</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Prevalence Rates of Borderline Personality Disorder Symptoms: A Study Based on the Netherlands Mental Health Survey and Incidence Study&#x02010;2</article-title>.&#x0201d; <source>BMC Psychiatry</source>
<volume>16</volume>, no. <issue>1</issue>: <fpage>249</fpage>. <pub-id pub-id-type="doi">10.1186/s12888-016-0939-x</pub-id>.<pub-id pub-id-type="pmid">27435813</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0049"><mixed-citation publication-type="journal" id="pmh70014-cit-0049">
<string-name>
<surname>Tennant</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Frampton</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Mulder</surname>
</string-name>, and <string-name>
<given-names>B. B.</given-names>
<surname>Background</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Polypharmacy in the Treatment of People Diagnosed With Borderline Personality Disorder: Repeated Cross&#x02010;Sectional Study Using new Zealand's National Databases</article-title>.&#x0201d; <source>BJPsych Open</source>
<volume>9</volume>, no. <issue>6</issue>: <elocation-id>e200</elocation-id>. <pub-id pub-id-type="doi">10.1192/BJO.2023.592</pub-id>.<pub-id pub-id-type="pmid">37881020</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0050"><mixed-citation publication-type="journal" id="pmh70014-cit-0050">
<string-name>
<surname>Tong</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Flemming</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>McInnes</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Oliver</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Craig</surname>
</string-name>. <year>2012</year>. &#x0201c;<article-title>Enhancing Transparency in Reporting the Synthesis of Qualitative Research: ENTREQ</article-title>.&#x0201d; <source>BMC Medical Research Methodology</source>
<volume>12</volume>, no. <issue>1</issue>: <fpage>181</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2288-12-181</pub-id>.<pub-id pub-id-type="pmid">23185978</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0066"><mixed-citation publication-type="journal" id="pmh70014-cit-0066">
<string-name>
<surname>Tong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Costello</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>McCabe</surname>
</string-name>, and <string-name>
<given-names>A. M.</given-names>
<surname>Doherty</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Borderline Personality Disorder in Irish Travellers: A Cross&#x02010;Sectional Study of an Ultra&#x02010;High&#x02010;Risk Group</article-title>.&#x0201d; <source>Irish Journal of Medical Science</source>
<volume>190</volume>, no. <issue>2</issue>: <fpage>735</fpage>&#x02013;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1007/s11845-020-02369-2</pub-id>.<pub-id pub-id-type="pmid">32920694</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0051"><mixed-citation publication-type="journal" id="pmh70014-cit-0051">
<string-name>
<surname>van Asselt</surname>, <given-names>A. D. I.</given-names>
</string-name>, <string-name>
<given-names>C. D.</given-names>
<surname>Dirksen</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Arntz</surname>
</string-name>, and <string-name>
<given-names>J. L.</given-names>
<surname>Severens</surname>
</string-name>. <year>2007</year>. &#x0201c;<article-title>The Cost of Borderline Personality Disorder: Societal Cost of Illness in BPD&#x02010;Patients</article-title>.&#x0201d; <source>European Psychiatry</source>
<volume>22</volume>, no. <issue>6</issue>: <fpage>354</fpage>&#x02013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1016/j.eurpsy.2007.04.001</pub-id>.<pub-id pub-id-type="pmid">17544636</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0052"><mixed-citation publication-type="journal" id="pmh70014-cit-0052">
<string-name>
<surname>van der Bles</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Linden</surname>
</string-name>, <string-name>
<given-names>A. L. J.</given-names>
<surname>Freeman</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Communicating Uncertainty About Facts, Numbers and Science</article-title>.&#x0201d; <source>Royal Society Open Science</source>
<volume>6</volume>, no. <issue>5</issue>: <elocation-id>181870</elocation-id>. <pub-id pub-id-type="doi">10.1098/rsos.181870</pub-id>.<pub-id pub-id-type="pmid">31218028</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0053"><mixed-citation publication-type="journal" id="pmh70014-cit-0053">
<string-name>
<surname>Wlodarczyk</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Lawn</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Powell</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Exploring General Practitioners' Views and Experiences of Providing Care to People With Borderline Personality Disorder in Primary Care: A Qualitative Study in Australia</article-title>.&#x0201d; <source>International Journal of Environmental Research and Public Health</source>
<volume>15</volume>, no. <issue>12</issue>: <elocation-id>2763</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijerph15122763</pub-id>.<pub-id pub-id-type="pmid">30563256</pub-id>
</mixed-citation></ref><ref id="pmh70014-bib-0054"><mixed-citation publication-type="miscellaneous" id="pmh70014-cit-0054">
<collab collab-type="authors">World Health Organization</collab>
. <year>2019</year>. &#x0201c;<article-title>ICD&#x02010;11: International Classification of Diseases 11th Revision: The Global Standard for Diagnostic Health Information</article-title>.&#x0201d; World Health Organization. <ext-link xlink:href="https://icd.who.int/" ext-link-type="uri">https://icd.who.int/</ext-link>.</mixed-citation></ref><ref id="pmh70014-bib-0055"><mixed-citation publication-type="journal" id="pmh70014-cit-0055">
<string-name>
<surname>Zanarini</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<given-names>J. G.</given-names>
<surname>Gunderson</surname>
</string-name>, <string-name>
<given-names>F. R.</given-names>
<surname>Frankenburg</surname>
</string-name>, and <string-name>
<given-names>D. L.</given-names>
<surname>Chauncey</surname>
</string-name>. <year>1989</year>. &#x0201c;<article-title>The Revised Diagnostic Interview for Borderlines: Discriminating BPD From Other axis II Disorders</article-title>.&#x0201d; <source>Journal of Personality Disorders</source>
<volume>3</volume>, no. <issue>1</issue>: <fpage>10</fpage>&#x02013;<lpage>18</lpage>.</mixed-citation></ref></ref-list><app-group><app id="pmh70014-app-0001" content-type="Appendix"><label>Appendix A</label><p>
<table-wrap position="anchor" id="jats-table-wrap-1"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Section and topic</th><th align="center" valign="bottom" rowspan="1" colspan="1">Item #</th><th align="center" valign="bottom" rowspan="1" colspan="1">Checklist item</th><th align="center" valign="bottom" rowspan="1" colspan="1">Location where item is reported</th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Title</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Title</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Identify the report as a systematic review.</td><td align="center" valign="top" rowspan="1" colspan="1">Yes &#x02013; TITLE</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Abstract</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abstract</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">See the PRISMA 2020 for Abstracts checklist.</td><td align="center" valign="top" rowspan="1" colspan="1">TBC</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Introduction</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rationale</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the rationale for the review in the context of existing knowledge.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Objectives</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Provide an explicit statement of the objective(s) or question(s) the review addresses.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 8</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Methods</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Eligibility criteria</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Page 9</p>
<p>Page 11</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Information sources</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Yes</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Search strategy</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">Present the full search strategies for all databases, registers and websites, including any filters and limits used.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Selection process</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 10&#x02009;+&#x02009;Prisma Diagram</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Data collection process</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 10</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Data items</td><td align="center" valign="top" rowspan="1" colspan="1">10a</td><td align="center" valign="top" rowspan="1" colspan="1">List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect.</td><td align="center" valign="top" rowspan="1" colspan="1">Appendix</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">10b</td><td align="center" valign="top" rowspan="1" colspan="1">List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.</td><td align="center" valign="top" rowspan="1" colspan="1">Appendix</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study risk of bias assessment</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Effect measures</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results.</td><td align="center" valign="top" rowspan="1" colspan="1">Table&#x000a0;<xref rid="pmh70014-tbl-0002" ref-type="table">2</xref> and <xref rid="pmh70014-tbl-0003" ref-type="table">3</xref>
</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">Synthesis methods</td><td align="center" valign="top" rowspan="1" colspan="1">13a</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).</td><td align="center" valign="top" rowspan="1" colspan="1">Page 11</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13b</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 11</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13c</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any methods used to tabulate or visually display results of individual studies and syntheses.</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13d</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any methods used to synthesise results and provide a rationale for the choice(s). If meta&#x02010;analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 11</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13e</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta&#x02010;regression).</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13f</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any sensitivity analyses conducted to assess robustness of the synthesised results.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reporting bias assessment</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Certainty assessment</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Results</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Study selection</td><td align="center" valign="top" rowspan="1" colspan="1">16a</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.</td><td align="center" valign="top" rowspan="1" colspan="1">Prisma Diagram</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16b</td><td align="center" valign="top" rowspan="1" colspan="1">Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study characteristics</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">Cite each included study and present its characteristics.</td><td align="center" valign="top" rowspan="1" colspan="1">Table&#x000a0;<xref rid="pmh70014-tbl-0001" ref-type="table">1</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Risk of bias in studies</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">Present assessments of risk of bias for each included study.</td><td align="center" valign="top" rowspan="1" colspan="1">Appendix MMAT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Results of individual studies</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots.</td><td align="center" valign="top" rowspan="1" colspan="1">Table&#x000a0;<xref rid="pmh70014-tbl-0002" ref-type="table">2</xref> &#x00026; <xref rid="pmh70014-tbl-0003" ref-type="table">3</xref>
</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Results of syntheses</td><td align="center" valign="top" rowspan="1" colspan="1">20a</td><td align="center" valign="top" rowspan="1" colspan="1">For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 25</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20b</td><td align="center" valign="top" rowspan="1" colspan="1">Present results of all statistical syntheses conducted. If meta&#x02010;analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20c</td><td align="center" valign="top" rowspan="1" colspan="1">Present results of all investigations of possible causes of heterogeneity among study results.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 8 &#x00026; 13</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20d</td><td align="center" valign="top" rowspan="1" colspan="1">Present results of all sensitivity analyses conducted to assess the robustness of the synthesised results.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reporting biases</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Certainty of evidence</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.</td><td align="center" valign="top" rowspan="1" colspan="1">Table&#x000a0;<xref rid="pmh70014-tbl-0003" ref-type="table">3</xref>
</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Discussion</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Discussion</td><td align="center" valign="top" rowspan="1" colspan="1">23a</td><td align="center" valign="top" rowspan="1" colspan="1">Provide a general interpretation of the results in the context of other evidence.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 23</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">23b</td><td align="center" valign="top" rowspan="1" colspan="1">Discuss any limitations of the evidence included in the review.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 25</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">23c</td><td align="center" valign="top" rowspan="1" colspan="1">Discuss any limitations of the review processes used.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 25</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">23d</td><td align="center" valign="top" rowspan="1" colspan="1">Discuss implications of the results for practice, policy, and future research.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 25/26</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">
<bold>Other information</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Registration and protocol</td><td align="center" valign="top" rowspan="1" colspan="1">24a</td><td align="center" valign="top" rowspan="1" colspan="1">Provide registration information for the review, including register name and registration number, or state that the review was not registered.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 21</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">24b</td><td align="center" valign="top" rowspan="1" colspan="1">Indicate where the review protocol can be accessed, or state that a protocol was not prepared.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 21</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">24c</td><td align="center" valign="top" rowspan="1" colspan="1">Describe and explain any amendments to information provided at registration or in the protocol.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Support</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">Describe sources of financial or nonfinancial support for the review, and the role of the funders or sponsors in the review.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Competing interests</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">Declare any competing interests of review authors.</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Availability of data, code and other materials</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">Report which of the following are publicly available and where they can be found:template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.</td><td align="center" valign="top" rowspan="1" colspan="1">Page 21 and Appendix</td></tr></tbody></table><table-wrap-foot id="pmh70014-ntgp-0005"><fn id="pmh70014-note-0006"><p>
<italic toggle="yes">Source:</italic> Page et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0027" ref-type="bibr">2021</xref>)</p></fn></table-wrap-foot></table-wrap>
</p></app><app id="pmh70014-app-0002" content-type="Appendix"><label>Appendix B</label><sec id="pmh70014-sec-0033"><label>B1</label><title>Search Terms</title><p>((&#x02018;borderline state&#x02019; OR &#x02018;borderline personality disorder&#x02019; OR eupd) AND (&#x02018;factors&#x02019; OR &#x02018;influences&#x02019; OR &#x02018;perspectives&#x02019; OR &#x02018;experiences&#x02019; OR &#x02018;doctor&#x02010;patient relationship&#x02019;)) AND (prescribing OR &#x02018;practice of prescribing&#x02019;)</p><p>Whenever possible, the following filters will be used:
<list list-type="bullet" id="pmh70014-list-0002"><list-item id="pmh70014-li-0005"><p>Date (publication year) 1994&#x02013;2023. A filter on the date of publication from 1994 to present will be utilised due to significant changes in diagnosis criteria for BPD in 1994, with the implementation of DSM&#x02010;IV.</p></list-item><list-item id="pmh70014-li-0006"><p>Languages. A filter restricted to English only, as the authors are limited to the English language and unable to properly analyse non&#x02010;English work.</p></list-item></list>
</p></sec></app><app id="pmh70014-app-0003" content-type="Appendix"><label>Appendix C</label><sec id="pmh70014-sec-0034"><label>C.1</label><title>The Data Extract Template</title><p>
<boxed-text position="anchor" content-type="graphic"><graphic xlink:href="PMH-19-0-g001.jpg" position="anchor" id="jats-graphic-3"/></boxed-text>
</p></sec></app><app id="pmh70014-app-0004" content-type="Appendix"><label>Appendix D</label><sec id="pmh70014-sec-0035"><label>D.1</label><p>
<table-wrap position="anchor" id="jats-table-wrap-2"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Item</th><th align="center" valign="bottom" rowspan="1" colspan="1">Guide and description</th><th align="center" valign="bottom" rowspan="1" colspan="1">Page</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Aim</td><td align="center" valign="top" rowspan="1" colspan="1">State the research question the synthesis addresses.</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Synthesis methodology</td><td align="center" valign="top" rowspan="1" colspan="1">Identify the synthesis methodology or theoretical framework which underpins the synthesis, and describe the rationale for choice of methodology (e.g., <italic toggle="yes">meta&#x02010;ethnography</italic>, <italic toggle="yes">thematic synthesis</italic>, <italic toggle="yes">critical interpretive synthesis</italic>, <italic toggle="yes">grounded theory synthesis</italic>, <italic toggle="yes">realist synthesis</italic>, <italic toggle="yes">meta&#x02010;aggregation</italic>, <italic toggle="yes">meta&#x02010;study</italic>, <italic toggle="yes">framework synthesis</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">6,7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Approach to searching</td><td align="center" valign="top" rowspan="1" colspan="1">Indicate whether the search was pre&#x02010;planned (<italic toggle="yes">comprehensive search strategies to seek all available studies</italic>) or iterative (<italic toggle="yes">to seek all available concepts until they theoretical saturation is achieved</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Inclusion criteria</td><td align="center" valign="top" rowspan="1" colspan="1">Specify the inclusion/exclusion criteria (e.g., <italic toggle="yes">in terms of population</italic>, <italic toggle="yes">language</italic>, <italic toggle="yes">year limits</italic>, <italic toggle="yes">type of publication</italic>, <italic toggle="yes">study type</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Data sources</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the information sources used (e.g., <italic toggle="yes">electronic databases</italic> (<italic toggle="yes">MEDLINE</italic>, <italic toggle="yes">EMBASE</italic>, <italic toggle="yes">CINAHL</italic>, <italic toggle="yes">psycINFO</italic>, <italic toggle="yes">Econlit</italic>), <italic toggle="yes">grey literature databases</italic> (<italic toggle="yes">digital thesis</italic>, <italic toggle="yes">policy reports</italic>), <italic toggle="yes">relevant organisational websites</italic>, <italic toggle="yes">experts</italic>, <italic toggle="yes">information specialists</italic>, <italic toggle="yes">generic web searches</italic> (<italic toggle="yes">Google Scholar</italic>) <italic toggle="yes">hand searching</italic>, <italic toggle="yes">reference lists</italic>) and when the searches conducted; provide the rationale for using the data sources.</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Electronic Search strategy</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the literature search (e.g., <italic toggle="yes">provide electronic search strategies with population terms</italic>, <italic toggle="yes">clinical or health topic terms</italic>, <italic toggle="yes">experiential or social phenomena related terms</italic>, <italic toggle="yes">filters for qualitative research and search limits</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>5 &#x00026;</p>
<p>Appendices</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">Study screening methods</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the process of study screening and sifting (e.g., <italic toggle="yes">title</italic>, <italic toggle="yes">abstract and full text review</italic>, <italic toggle="yes">number of independent reviewers who screened studies</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">Study characteristics</td><td align="center" valign="top" rowspan="1" colspan="1">Present the characteristics of the included studies (e.g., <italic toggle="yes">year of publication</italic>, <italic toggle="yes">country</italic>, <italic toggle="yes">population</italic>, <italic toggle="yes">number of participants</italic>, <italic toggle="yes">data collection</italic>, <italic toggle="yes">methodology</italic>, <italic toggle="yes">analysis</italic>, <italic toggle="yes">research questions</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">Table&#x000a0;<xref rid="pmh70014-tbl-0001" ref-type="table">1</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">Study selection results</td><td align="center" valign="top" rowspan="1" colspan="1">Identify the number of studies screened and provide reasons for study exclusion (e.g., <italic toggle="yes">for comprehensive searching</italic>, <italic toggle="yes">provide numbers of studies screened and reasons for exclusion indicated in a figure/flowchart; for iterative searching describe reasons for study exclusion and inclusion based on modifications the research question and/or contribution to theory development</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">Prisma Diagram&#x000a0;1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">Rationale for appraisal</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the rationale and approach used to appraise the included studies or selected findings (e.g., <italic toggle="yes">assessment of conduct</italic> [<italic toggle="yes">validity and robustness</italic>], <italic toggle="yes">assessment of reporting</italic> [<italic toggle="yes">transparency</italic>], <italic toggle="yes">assessment of content and utility of the findings</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Appraisal items</td><td align="center" valign="top" rowspan="1" colspan="1">State the tools, frameworks and criteria used to appraise the studies or selected findings (e.g., <italic toggle="yes">Existing tools:CASP</italic>, <italic toggle="yes">QARI</italic>, <italic toggle="yes">COREQ</italic>, <italic toggle="yes">Mays and Pope</italic> [25]<italic toggle="yes">; reviewer developed tools; describe the domains assessed:research team</italic>, <italic toggle="yes">study design</italic>, <italic toggle="yes">data analysis and interpretations</italic>, <italic toggle="yes">reporting</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">Appraisal process</td><td align="center" valign="top" rowspan="1" colspan="1">Indicate whether the appraisal was conducted independently by more than one reviewer and if consensus was required.</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">Appraisal results</td><td align="center" valign="top" rowspan="1" colspan="1">Present results of the quality assessment and indicate which articles, if any, were weighted/excluded based on the assessment and give the rationale.</td><td align="center" valign="top" rowspan="1" colspan="1">Appendices</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">Data extraction</td><td align="center" valign="top" rowspan="1" colspan="1">Indicate which sections of the primary studies were analysed and how were the data extracted from the primary studies? (e.g., <italic toggle="yes">all text under the headings &#x0201c;results/conclusions&#x0201d; were extracted electronically and entered into a computer software</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">6 &#x00026; appendices</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">Software</td><td align="center" valign="top" rowspan="1" colspan="1">State the computer software used, if any.</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">Number of reviewers</td><td align="center" valign="top" rowspan="1" colspan="1">Identify who was involved in coding and analysis.</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">Coding</td><td align="center" valign="top" rowspan="1" colspan="1">Describe the process for coding of data (e.g., <italic toggle="yes">line by line coding to search for concepts</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">6, 7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">Study comparison</td><td align="center" valign="top" rowspan="1" colspan="1">Describe how were comparisons made within and across studies (e.g., <italic toggle="yes">subsequent studies were coded into preexisting concepts</italic>, <italic toggle="yes">and new concepts were created when deemed necessary</italic>).</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">Derivation of themes</td><td align="center" valign="top" rowspan="1" colspan="1">Explain whether the process of deriving the themes or constructs was inductive or deductive.</td><td align="center" valign="top" rowspan="1" colspan="1">6, 7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">Quotations</td><td align="center" valign="top" rowspan="1" colspan="1">Provide quotations from the primary studies to illustrate themes/constructs, and identify whether the quotations were participant quotations of the author's interpretation.</td><td align="center" valign="top" rowspan="1" colspan="1">11&#x02013;13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">Synthesis output</td><td align="center" valign="top" rowspan="1" colspan="1">Present rich, compelling and useful results that go beyond a summary of the primary studies (e.g., <italic toggle="yes">new interpretation</italic>, <italic toggle="yes">models of evidence</italic>, <italic toggle="yes">conceptual models</italic>, <italic toggle="yes">analytical</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">13&#x02013;15</td></tr></tbody></table></table-wrap>
</p></sec></app><app id="pmh70014-app-0005" content-type="Appendix"><label>Appendix E</label><p>
<table-wrap position="anchor" id="jats-table-wrap-3"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Reference</th><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">1. Qualitative studies</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">1.1. Is the qualitative approach appropriate to answer the research question?</th><th align="center" valign="bottom" rowspan="1" colspan="1">1.2. Are the qualitative data collection methods adequate to address the research question?</th><th align="center" valign="bottom" rowspan="1" colspan="1">1.3. Are the findings adequately derived from the data?</th><th align="center" valign="bottom" rowspan="1" colspan="1">1.4. Is the interpretation of results sufficiently substantiated by data?</th><th align="center" valign="bottom" rowspan="1" colspan="1">1.5. Is there coherence between qualitative data sources, collection, analysis and interpretation?</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Wlodarczyk et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0053" ref-type="bibr">2018</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Cannot tell</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Martean and Evans&#x000a0;(<xref rid="pmh70014-bib-0022" ref-type="bibr">2014</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Cannot tell</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patel and Konstantinidou (<xref rid="pmh70014-bib-0031" ref-type="bibr">2020</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Cannot tell</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dickens et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0013" ref-type="bibr">2016</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table></table-wrap>
</p><sec id="pmh70014-sec-0037"><p>
<table-wrap position="anchor" id="jats-table-wrap-4"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Reference</th><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">4. Quantitative Descriptive Studies</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">4.1. Is the sampling strategy relevant to address the research question?</th><th align="center" valign="bottom" rowspan="1" colspan="1">4.2. Is the sample representative of the target population?</th><th align="center" valign="bottom" rowspan="1" colspan="1">4.3. Are the measurements appropriate?</th><th align="center" valign="bottom" rowspan="1" colspan="1">4.4. Is the risk of nonresponse bias low?</th><th align="center" valign="bottom" rowspan="1" colspan="1">4.5. Is the statistical analysis appropriate to answer the research question?</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0030" ref-type="bibr">2010</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes&#x02014;for specialist service</td><td align="center" valign="top" rowspan="1" colspan="1">Yes&#x02014;for specialist service</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tong et&#x000a0;al. (<xref rid="pmh70014-bib-0066" ref-type="bibr">2021</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes&#x02014;for specialist service</td><td align="center" valign="top" rowspan="1" colspan="1">Yes&#x02014;for specialist service</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0029" ref-type="bibr">2021</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Knappich et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0017" ref-type="bibr">2014</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schulkens et&#x000a0;al. (<xref rid="pmh70014-bib-0068" ref-type="bibr">2021</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Javed et&#x000a0;al. (<xref rid="pmh70014-bib-0069" ref-type="bibr">2022</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Cannot tell</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pascual et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0028" ref-type="bibr">2007</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Crawford et&#x000a0;al.&#x000a0;(<xref rid="pmh70014-bib-0011" ref-type="bibr">2011</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mirhaj Mohammadabadi et&#x000a0;al. (<xref rid="pmh70014-bib-0067" ref-type="bibr">2022</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Cannot tell</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table></table-wrap>
</p></sec></app></app-group></back></article>